<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Virol Methods</journal-id><journal-id journal-id-type="iso-abbrev">J Virol Methods</journal-id><journal-title-group><journal-title>Journal of Virological Methods</journal-title></journal-title-group><issn pub-type="ppub">0166-0934</issn><issn pub-type="epub">1879-0984</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7826042</article-id><article-id pub-id-type="pii">S0166-0934(21)00009-4</article-id><article-id pub-id-type="doi">10.1016/j.jviromet.2021.114070</article-id><article-id pub-id-type="publisher-id">114070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antiviral activity of bioactive phytocompounds against coronavirus: An update</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Bhattacharya</surname><given-names>Riya</given-names></name></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Dev</surname><given-names>Kamal</given-names></name></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Sourirajan</surname><given-names>Anuradha</given-names></name><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005">Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Bajhol, PO Sultanpur, District Solan, 173229, Himachal Pradesh, India</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Faculty of Applied Sciences and Biotechnology, Shoolini University, PO Box 9, Head Post Office, The Mall, Solan, Himachal Pradesh, 173212, India.</corresp></author-notes><pub-date pub-type="pmc-release"><day>23</day><month>1</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>4</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>23</day><month>1</month><year>2021</year></pub-date><volume>290</volume><fpage>114070</fpage><lpage>114070</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>25</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="graphical" id="abs0005"><title>Graphical abstract</title><fig id="fig0035" position="anchor"><graphic xlink:href="ga1_lrg"/></fig></abstract><abstract id="abs0015"><p>Viral infections are one of the main cause of diseases worldwide due to the rising trends of migration, urbanization and global mobility of humans. The outbreak of corona virus diseases caused by SARS-CoV (year 2003), MERS-CoV (year 2012) and SARS-CoV-2 (year 2019) raised global health concerns. The side effects associated with the conventional drugs and increase in cases of anti-microbial resistance have led the researchers to switch to natural sources, especially plants, as they have immense potential to be used as antiviral agents. The aim of the article is to summarize the evidences of the bioactive phytocompounds from different plants as an effective alternative for the treatment of infections caused by coronaviruses. However, the use of most plant compounds succumbs to limitations due to lack of experimental evidences and safety studies. Therefore, further research and studies are required to validate their therapeutic uses for wide application of plant-based medicine, including anti-virals.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Phytocompounds</kwd><kwd>SARS-CoV</kwd><kwd>MERS-CoV</kwd><kwd>Antiviral</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19, mechanism</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0020">The emerging trends in migration, urbanization and global travel have made viral outbreaks as an alarming threat for human health. Viral infections are of serious concern due to their complexity, diversity and limited availability of vaccines and antiviral therapies. As a result, they commonly lead to epidemic and pandemic events (<xref rid="bib0150" ref-type="bibr">Drexler, 2010</xref>; <xref rid="bib0330" ref-type="bibr">Neiderud, 2015</xref>). The treatment and control of viral infections largely depends on the availability of antiviral drugs, which are few in number and most of them do not act directly on virus, rather prevent their replication in the host. Viruses consist of a genome (either RNA or DNA) surrounded by a protein or lipid&#x02010;containing envelope, and the latter facilitates the viral entry into host cells resulting in several ailments like warts, colds, fever, or even death (<xref rid="bib0425" ref-type="bibr">Tapparel et al., 2013</xref>).</p><p id="par0025">Viruses survive and replicate in the host by hijacking the metabolic pathways of the host cells. Therefore, it is difficult to design an appropriate drug to attack the virus without triggering any adverse effects on the host. Consequently, the unique features of viruses (specificity, affinity, and self&#x02010;defense mechanisms), and the limitations of antiviral chemotherapy necessitate the dire need to develop new antiviral agents, which possess efficient selectivity, strength, <italic>in vivo</italic> stability and safety profiles (<xref rid="bib0005" ref-type="bibr">Akram et al., 2018</xref>).</p><p id="par0030">The Coronaviridae family comprises of enveloped single-stranded RNA viruses that are generally causative agents of common cold, upper respiratory disorders and lower respiratory infections, especially in elderly persons and children, who have weak immune system. Currently, there is an outbreak caused by a novel subtype of coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), which has resulted in a pandemic with millions of infections and deaths worldwide in humans. The novel coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has become a global health concern since December 2019 till date. In this context, it is extremely important to understand the mechanism of the SARS-CoV-2 viral pathogenesis to develop specific and effective drugs. Currently, it has been reported that SARS-CoV-2 shows sequence homology with the SARS-CoV and a bat coronavirus (<xref rid="bib0205" ref-type="bibr">Gorbalenya et al., 2020</xref>). Despite its similarity to SARS-CoV, its transmission efficiency and diagnostic methods are very different, and SARS-CoV-2 is much more virulent compared to SARS-CoV-1. This could possibly be due to the nucleotide changes in the spike (S) protein and its receptor-binding domain (RBD) (<xref rid="bib0250" ref-type="bibr">Kannan et al., 2020</xref>; <xref rid="bib0105" ref-type="bibr">Coutard et al., 2020</xref>; <xref rid="bib0440" ref-type="bibr">Wan et al., 2020</xref>). Therefore, scientists worldwide are exploring the preventive methods and treatment for COVID-19, until a vaccine will be available (<xref rid="bib0020" ref-type="bibr">Balachandar et al., 2020</xref>).</p><p id="par0035">As the world is awaiting curative remedies for COVID-19, there have been several attempts in the recent past towards repositioning of existing drugs to combat the spread of COVID-19. The World Health Organization (WHO) estimates that about 80 % of global population rely on traditional medicine to treat infectious diseases (<xref rid="bib0340" ref-type="bibr">Pan et al., 2013</xref>). Several <italic>in vitro</italic> and <italic>in vivo</italic> studies carried out on plants and their derived products have helped to develop effective antibiotic, antimitotic, and antiviral activities. In addition, the pharmaceutical companies began to develop new antimicrobial drugs from natural plant sources (<xref rid="bib0035" ref-type="bibr">Barreca et al., 2017</xref>). The evaluation of several medicinal plants revealed their potential to be used as therapeutic agents against different viruses (<xref rid="bib0005" ref-type="bibr">Akram et al., 2018</xref>). The available antiviral drugs act on specific enzymes involved in targeting the viral structure or in the replication cycle, making them effective targets. But the failure of several conventional drugs against viral infections and the rise in incidence of specific viral resistance has led to an interest in plants as an alternative source of effective antiviral agents (<xref rid="bib0235" ref-type="bibr">Irwin et al., 2016</xref>). Different plant components including essential oils and phytocompounds, such as phenolic acids, flavonoids, terpenes, lignans, coumarins, and alkaloids exhibit potential activity against viruses (<xref rid="bib0110" ref-type="bibr">Daglia, 2012</xref>). Thus, medicinal plants are a promising source for treatment viral diseases (<xref rid="bib0195" ref-type="bibr">Gomathi et al., 2020</xref>).</p><p id="par0040">With the onset of COVID-19 pandemic, research has been initiated to screen the potential of several plant secondary metabolites in inhibiting the SARS-CoV-2 main protease (M<sup>pro</sup>)/chymotrypsin-like protease (3CL<sup>pro</sup>) using molecular docking analysis to examine binding affinity. However, screening a large number of medicinal plants for phytocompounds with antiviral activity against SARS-CoV-2 will be a challenge in very short period of time. Drug discovery is a time consuming, slow and challenging process (<xref rid="bib0400" ref-type="bibr">Shaikh et al., 2013</xref>; <xref rid="bib0160" ref-type="bibr">Eweas et al., 2014</xref>). Thus, it is necessary to exploit computational tools for new drug development, which has made the process of drug discovery rapid and cost effective in the past (<xref rid="bib0160" ref-type="bibr">Eweas et al., 2014</xref>). For screening and searching phytocompounds, the ligand-based virtual screening tool/ molecular docking is very effective to identify most probable molecule with pharmacological activity (<xref rid="bib0210" ref-type="bibr">Guo et al., 2014</xref>; <xref rid="bib0025" ref-type="bibr">Banegas et al., 2018</xref>).</p><p id="par0045">The aim of this review is to provide an update on the antiviral activity of different medicinal plants and their isolated bioactive phytocompounds, their mechanism of action and potential interactions with conventional drugs. The review focuses on the literature available on structure, immunological influence, mechanism of action of the phytocompounds, ongoing clinical trials, recent diagnostics and the potential use of certain medicinal herbs for the effective treatment of coronavirus. Based on the review of literature, we suggest that the traditional medicinal plants can be used as a beneficial and effective means to combat viruses like the SARS-CoV-1, MERS-CoV and SARS-CoV-2.</p></sec><sec id="sec0010"><label>2</label><title>Overview of coronaviruses</title><p id="par0050">There are total 39 species of coronaviruses under the realm of Riboviria, which belong to the family Coronaviridae, suborder Cornidovirineae and order Nidovirales (<xref rid="bib0205" ref-type="bibr">Gorbalenya et al., 2020</xref>). All the SARS-CoV viruses fall under the species severe acute respiratory syndrome-related coronavirus and genus Beta-coronavirus. Most of the species are enzootic and only few species infect humans (<xref rid="bib0390" ref-type="bibr">Schoeman and Fielding, 2019</xref>). So far, seven human CoVs (HCoVs) have been reported, which include, human coronavirus NL63 (HCoV-NL63) and human coronavirus 229E (HCoV-229E) of the alpha-coronavirus genus, and human coronavirus OC43 (HCoV&#x02212;OC43), human coronavirus (HCoV-HKU1), SARS-CoV, SARS-CoV-2 and middle east respiratory syndrome coronavirus (MERS-CoV) of the beta-coronavirus genus. Human coronaviruses are mostly associated with upper respiratory tract infection, which ranges from mild to moderate, including common cold. It is believed that most of the people might have been infected with one of these viruses at some point in their lifetime (<xref rid="bib0260" ref-type="bibr">Killerby et al., 2018</xref>).</p><p id="par0055">The SARS-CoV and MERS-CoV are the two major viruses that are responsible for severe pneumonia in humans (<xref rid="bib0420" ref-type="bibr">Song et al., 2019</xref>). The emergence of SARS-CoV was first reported in 2003, which led to more than 8000 infections and 774 deaths spread across 37 countries (<xref rid="bib0355" ref-type="bibr">Peiris et al., 2004</xref>). This was followed by the emergence of MERS-CoV in Saudi Arabia in 2012, which was responsible for 858 deaths out of 2494 infections (<xref rid="bib0520" ref-type="bibr">Zaki et al., 2012</xref>). Subsequently, an outbreak of SARS-CoV-2 emerged in December 2019 in the city of Wuhan, China from animal source and transmitted to human population, resulting in the COVID-19 pandemic with lakhs of deaths and millions of infected cases all over the world. As of October 11, 2020, the World Health Organization (WHO) has reported 37,109,851 infections in humans and 1,070,355 deaths worldwide due to COVID-19, and its spread to 214 countries and territories (<xref rid="bib0485" ref-type="bibr">World Health Organization (WHO, 2020a</xref>,<xref rid="bib0475" ref-type="bibr">b</xref>). To combat the battle against this dreadful virus, the WHO has strategized the following measures: to avoid human to human contact, maintaining social distancing and isolate patients at early stages, identify and stop its transmission from the animal source, finding out crucial aspects of the virus and speed up research activities for its prevention and cure, dissemination of appropriate directions to the public and minimize the social and economic impact.</p><p id="par0060">The SARS-CoV-2 is a zoonotic virus that belongs to the coronaviridae family and can infect humans and several other animal species (<xref rid="bib0295" ref-type="bibr">Lu et al., 2020</xref>). The SARS-CoV-2 belongs to the subgenus sarbecovirus and mostly similar to bat coronavirus, with 96.2 % sequence homology (<xref rid="bib0060" ref-type="bibr">Chan et al., 2020a</xref>). The appearance of symptoms due to SARS-CoV-2 infection occurs slowly over an incubation period of around 2 weeks. During this incubation period, the virus replicates in the upper and lower respiratory tract, forming lesions (<xref rid="bib0065" ref-type="bibr">Chan et al., 2020b</xref>). The common symptoms reported in the infected individuals are loss of taste, fever, cough, dyspnea and lesion in the lungs (<xref rid="bib0225" ref-type="bibr">Huang et al., 2020</xref>). The key proteases of the SARS-CoV namely 3C- like Protease (3CL<sup>pro</sup>) and the Papain-like protease (PL<sup>pro</sup>) are potential targets for the development of inhibitors against SARS-CoV (<xref rid="bib0100" ref-type="bibr">Chou et al., 2003</xref>; <xref rid="bib0525" ref-type="bibr">Zhang and Yap, 2004</xref>; <xref rid="bib0010" ref-type="bibr">Anand et al., 2005</xref>). The 3CL<sup>pro</sup> and PL<sup>pro</sup> are the key enzymes involved in the processing of the non-structural proteins of the virus (<bold>nsp</bold>s) required for the viral replication (<xref rid="bib0015" ref-type="bibr">B&#x000e1;ez et al., 2015</xref>; <xref rid="bib0050" ref-type="bibr">Cascella et al., 2020</xref>). The surface of SARS-CoV is coated with the S proteins, which possess the potential to attach to human angiotensin converting enzyme 2 receptors (ACE2). ACE2 receptors are expressed in the lungs, kidney, endothelium, heart, and intestine (<xref rid="bib0530" ref-type="bibr">Zhang et al., 2020</xref>). An alternative way to block the activity of the SARS-CoV is to target its S protein or blocking the human ACE2 from binding to the S protein.</p></sec><sec id="sec0015"><label>3</label><title>Structural and genomic organization of coronaviruses</title><p id="par0065">The morphology of coronaviruses varies from spherical to pleomorphic shape, with a diameter of 80&#x02013;120 nm (<xref rid="bib0305" ref-type="bibr">Masters, 2006</xref>). Coronaviruses possess the ability to form double membrane vesicles (DMVs) in the infected cells. They also exhibit recombination, high rates of mutation, and propensity to cross species. The coronavirus genome consists of 6&#x02013;7 open reading frames (ORFs), as described below.</p><sec id="sec0020"><label>3.1</label><title>SARS-CoV</title><p id="par0070">The genome of SARS-CoV encodes the structural spike (S) glycoprotein, membrane (M) glycoprotein, small envelope (E) protein and nucleocapsid (N) protein in 5&#x002b9;- 3&#x002b9; direction within the 3&#x002b9; proximal 1/3<sup>rd</sup> region of the genome. All the SARS-CoV genomes harbor an extremely large gene 1 (separated into ORFs 1a and 1b and extending over two-thirds of the genome) encoding nonstructural proteins responsible for proteolytic processing of the gene 1 polyprotein products, virus genome replication, and sub-genomic (sg) mRNA synthesis (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>
).<fig id="fig0005"><label>Fig. 1</label><caption><p><bold>Schematic diagram of SARS-CoV structure and its genomic organization.</bold> The top panel depicts the structure of SARS- coronavirus, wherein the spike protein, envelope, and nucleocapsid are shown. Bottom panel: The genome organization map, which consists of genes encoding the structural spike (S) glycoprotein, membrane (M) glycoprotein, small envelope (E) protein and nucleocapsid (N) protein in 5&#x002b9;-3&#x002b9; direction within the 3&#x002b9; proximal 1/3<sup>rd</sup> of the genome. A variable number of different ORFs (ORF 1a and 2a) appearing to be virus- or group-specific, encoding nonstructural proteins, are also present on the proximal end. The figure was made with the help of Biorender.com.</p></caption><alt-text id="at0025">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="par0075">A variable number of ORFs appearing to be virus- or group-specific, encoding nonstructural proteins (nsps) are also present in the genome. These include ORF 3a (7.7 kDa protein), ORF 3b (27.7 kDa protein), and ORF 7 [0.7 kDa hydrophobic protein (HP)] in TGEV (Transmissible gastroenteritis coronavirus); ORF 3 (25.3 kDa protein) in PEDV(Porcine epidemic diarrhea coronavirus); ORF 4a (15.3 kDa protein) and ORF 4b (10.2 kDa protein) in HCoV-229E; ORF 2a (32 kDa protein), ORF 2b [65 kDa complete or 34.6 kDa truncated hemagglutinin esterase (HE) protein, depending on the strain], ORF 4 (17.8 kDa protein), ORF 5a (13.1 kDa protein), and an ORF internal to gene 7 [23 kDa internal (I) protein] in MHV (Mouse hepatitis coronavirus); ORF 2a (32 kDa protein), ORF 2b (65 kDa HE protein), ORF 4a (4.9 kDa protein), ORF 4b (4.8 kDa protein), ORF 5 (12.7 kDa protein), and an ORF internal to gene 7 (23 kDa I protein) in BCoV (Bovine coronavirus); and ORF 3a (6.7 kDa protein), ORF 3b (7.4 kDa protein), ORF 5a (7.5 kDa protein), and ORF 5b (9.5 kDa protein) in IBV (Avian coronavirus) (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>).</p><p id="par0080">The 5&#x02019;-untranslated region (UTRs) ranges in length from 209 to 528 nt and contains a similarly positioned short, AUG-initiated open reading frame (ORF) relative to the 5&#x002b9; end (<xref rid="bib0320" ref-type="bibr">Morris and Geballe, 2000</xref>).</p><p id="par0085">The 3&#x002b9; UTRs vary in length from 288 to 506 nt, with some strains of IBV having 3&#x02019; UTRs of greater length because of internal sequence duplications (<xref rid="bib0480" ref-type="bibr">Williams et al., 1993</xref>. They possess an octameric sequence of GGAAGAGC upstream of the 3&#x002b9;-terminal poly(A) tail.</p></sec><sec id="sec0025"><label>3.2</label><title>MERS-CoV</title><p id="par0090">The genome of MERS-CoV strain was reported to be 30,114 nucleotides (nt), including the 3&#x002b9; and 5&#x002b9; UTRs. The MERS-CoV exhibits structural genomic organization of betacoronavirus with the following components: 5&#x002b9;-untranslated region (UTR) (nt 1&#x02013;272), replicase complex ORF1ab (nt 273&#x02013;21508), S gene (nt 21450&#x02013;25511), ORF3 (nt 25526&#x02013;25837), ORF4a (nt 25846&#x02013;26175), ORF4b (nt 26087&#x02013;26827), ORF5 (nt26834 to 27,508), E gene (nt 27584&#x02013;27832), M gene (nt 27847&#x02013;28506), N gene (nt 28560&#x02013;29801), ORF8b (nt 28756&#x02013;29094), and 3&#x002b9; UTR (nt 29094&#x02013;30114) (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>
). The two essential poly-proteins namely pp1ab and pp1a are cleaved into 15/16 non-structural proteins (nsp) by 3CL<sup>pro</sup> and PL<sup>pro</sup>. The nsps include nsp12, nsp13, nsp14, nsp15, and nsp16. The nsp14 protein functions as proofreading enzyme, thereby curtailing the mutation rates during replication of the genomic RNA of coronavirus (<xref rid="bib0555" ref-type="bibr">Ziebuhr et al., 2000</xref>; <xref rid="bib0415" ref-type="bibr">Snijder et al., 2003</xref>; <xref rid="bib0200" ref-type="bibr">Gorbalenya et al., 2006</xref>; <xref rid="bib0410" ref-type="bibr">Smith et al., 2013</xref>; <xref rid="bib0360" ref-type="bibr">Raj et al., 2014</xref>; <xref rid="bib0155" ref-type="bibr">Durai et al., 2015</xref>). Studies have revealed that the accessory ORF proteins play an important role in MERS-CoV infection and pathogenesis (<xref rid="bib0310" ref-type="bibr">Menachery et al., 2017</xref>).<fig id="fig0010"><label>Fig. 2</label><caption><p><bold>MERS-CoV structure and genomic organization.</bold> The top panel shows the structure of MERS- coronavirus, wherein the spike protein, envelope, and nucleocapsid are shown. Bottom panel: The genome organization map of MERS-CoV, wherein the genes encoding the structural spike (S) glycoprotein, membrane (M) glycoprotein, small envelope (E) protein and nucleocapsid (N) protein in 5&#x002b9;-3&#x002b9; direction are shown within the 3&#x002b9; proximal 1/3<sup>rd</sup> of the genome. The genome size of MERS-CoV strain was reported to be 30,114 nucleotide (nt) long, including the 3&#x002b9; and 5&#x002b9; UTRs. The MERS-CoV also contains 5&#x002b9;-untranslated region (UTR), replicase complex ORF1ab, S gene, ORF3, ORF4a, ORF4b, ORF5, E gene, M gene, N gene, ORF8b gene and 3&#x002b9; UTR. The figure was made with the help of Biorender.com.</p></caption><alt-text id="at0030">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="par0095">The MERS-CoV has the potential to adjust and survive in new environments by acquiring various virulence factors and their transfer from one person to other during outbreak (<xref rid="bib0560" ref-type="bibr">Zumla et al., 2015</xref>). The phylogenetic analysis revealed that human and camel MERS-CoV were homologous to each other.</p></sec><sec id="sec0030"><label>3.3</label><title>SARS-CoV-2</title><p id="par0100">SARS&#x02010;CoV&#x02010;2 are spherical positive single&#x02010;stranded RNA viruses that are identified by the presence of S proteins projecting from the virion surface (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>
) (<xref rid="bib0335" ref-type="bibr">Neuman et al., 2006</xref>; <xref rid="bib0030" ref-type="bibr">B&#x000e1;rcena et al., 2009</xref>). The spherical shape of SARS-CoV-2 along with the spike projections led to the name coronavirus from the Latin word &#x0201c;corona&#x0201d; which means &#x0201c;crown&#x0201d;, because of the appearance of the virus as a royal crown under the electron microscope (<xref rid="bib0335" ref-type="bibr">Neuman et al., 2006</xref>; <xref rid="bib0030" ref-type="bibr">B&#x000e1;rcena et al., 2009</xref>).<fig id="fig0015"><label>Fig. 3</label><caption><p><bold>SARS-CoV-2 structural and genomic organization.</bold> S, M, and E proteins are located in the viral envelope but the N protein interacts with the viral RNA and is present in the core of the viral particle, forming the nucleocapsid. S protein exists as two subunits (S1 and S2) on the viral particle due to cleavage of S protein by host furin&#x02010;like proteases during viral replication. The SARS-CoV-2 genome has the following genes from 5&#x02019; to 3&#x02019;: replicase open reading frame (ORF) 1ab; S; envelope (E); membrane (M); and N. The figure was made with the help of Biorender.com.</p></caption><alt-text id="at0035">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p><p id="par0105">Recent studies have demonstrated that SARS-CoV-2 has a similar genomic organization to other beta-coronaviruses, containing 5&#x02032; UTR (265 nt), gene encoding a replicase complex (orf1ab), genes encoding non-structural proteins (nsps), S protein gene, E protein gene, M protein gene, N protein gene, 3&#x02032;-UTR (229 nt), and other non-structural ORFs (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>) (<xref rid="bib0545" ref-type="bibr">Zhu et al., 2020</xref>). The S, ORF3a, E, M, and N genes of SARS-CoV-2 comprise 3822, 828, 228, 669, and 1260 nucleotides, respectively (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>). Similar to SARS-CoV, SARS-CoV-2 carries a predicted ORF8 gene (366 nt in length) found between the M and N ORF genes (<xref rid="bib0490" ref-type="bibr">Wu et al., 2020a</xref>,<xref rid="bib0495" ref-type="bibr">b</xref>). However, SARS-CoV-2 is more diverse from MERS-CoV and SARS-CoV. Recent studies highlighted that SARS-CoV-2 genes share &#x0003c; 80 % nucleotide identity and 89.10 % nucleotide homology with their corresponding genes of SARS-CoV (<xref rid="bib0540" ref-type="bibr">Zhou et al., 2020</xref>; <xref rid="bib0490" ref-type="bibr">Wu et al., 2020a</xref>,<xref rid="bib0495" ref-type="bibr">b</xref>).</p><p id="par0110">The S, M, and E proteins are located in the viral envelope but the N protein interacts with the viral RNA and is present in the core of the viral particle, forming the nucleocapsid (<xref rid="bib0170" ref-type="bibr">Fehr and Perlman, 2015</xref>).</p><p id="par0115">The S protein is a glycosylated protein that is responsible for homotrimeric spikes on the surface of the viral particle and mediates viral entry into host (<xref rid="bib0045" ref-type="bibr">Bosch et al., 2003</xref>). S protein exists as two subunits (S1 and S2) on the viral particle due to cleavage of S protein by host furin&#x02010;like proteases during viral replication (<xref rid="bib0045" ref-type="bibr">Bosch et al., 2003</xref>; <xref rid="bib0240" ref-type="bibr">Izaguirre, 2019</xref>). The N protein binds with the viral RNA and is involved in packaging of viral RNA into the viral particle during viral assembly (<xref rid="bib0075" ref-type="bibr">Chang et al., 2006</xref>; <xref rid="bib0230" ref-type="bibr">Hurst et al., 2009</xref>). The M protein is one of the most important proteins in the virion structure. It is present in higher quantities than any other protein in the viral particle, while E protein is found in small quantities within the virion (<xref rid="bib0325" ref-type="bibr">Nal et al., 2005</xref>).</p><p id="par0120">Although the source of transmission of SARS-CoV-2 is as yet unclear, it is believed that humans were infected through an unidentified intermediary animal host (possibly bats) followed by intense and rapid spread from human-to humans (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>, <xref rid="fig0020" ref-type="fig">Fig. 4</xref>
). It is also believed that animals such as dogs, pigs might have served as intermediate host for SARS-CoV-2 (<xref rid="fig0020" ref-type="fig">Fig. 4</xref>). In the advanced stages, the SARS-CoV-2 virus manifests the symptoms of pneumonia in the patients, which progresses to acute respiratory distress syndrome (ARDS), resulting in the need for life-support to sustain the patient's life (<xref rid="bib0190" ref-type="bibr">Gatera and Pavarini, 2020</xref>). The current pandemic caused by SARS-CoV-2 is maintaining a sustained progression throughout the world, thus calling for an emergency international alarm for finding an effective cure and vaccine for this infection.<fig id="fig0020"><label>Fig. 4</label><caption><p><bold>Comparison of the receptor, hosts, number of cases and deaths (as per WHO data) in humans due to infection by SARS-CoV, MERS-CoV and SARS-CoV-2.</bold> The figure was made with the help of Biorender.com.</p></caption><alt-text id="at0040">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p></sec></sec><sec id="sec0035"><label>4</label><title>Current diagnostics and treatment for coronavirus infections</title><p id="par0125">During SARS-CoV and MERS-CoV outbreaks, diagnostic tools were developed for their accurate detection but they are not effective for detection of SARS-CoV-2. The nucleic acid detection of the viral particle is primarily used in SARS-CoV-2 diagnosis (<xref rid="bib0450" ref-type="bibr">Wang et al., 2020a</xref>, <xref rid="bib0455" ref-type="bibr">2020b</xref>, <xref rid="bib0460" ref-type="bibr">2020c</xref>).</p><p id="par0130">The collection of upper respiratory nasopharyngeal (NP) swabs for the diagnostic tests has been recommended (<xref rid="bib0055" ref-type="bibr">Centers for Disease Prevention and Control (CDC, 2020</xref>). The Charit&#x000e9; algorithm has two steps: the first step involves two reverse transcriptase PCR (RT-PCR) assays for genes encoding E protein and RNA- dependent RNA polymerase (RdRp) of Sarbecovirus subfamily; if both the tests are positive, the sample proceeds to the second step, wherein it is tested for SARS-CoV-2 specific RdRp by RT-PCR (<xref rid="bib0285" ref-type="bibr">Loeffelholz and Tang, 2020</xref>). However, these methods are cost-intensive, and thus cheaper alternatives have been developed to track the symptoms of COVID-19 such as smart-phone surveillance (<xref rid="bib0145" ref-type="bibr">Dorigatti et al., 2020</xref>). Imaging techniques are also used as a diagnostic method in COVID-19, including chest CT scans, which have been commonly used to detect lung abnormalities caused by SARS-CoV-2 infection (<xref rid="bib0405" ref-type="bibr">Shi et al., 2020</xref>; <xref rid="bib0500" ref-type="bibr">Xu et al., 2020a</xref>, <xref rid="bib0505" ref-type="bibr">b</xref>).</p><p id="par0135">The strategies used to halt the propagation of RNA viruses in host cells or tissues include inhibition of RNA transcription, RNA modification, virus packaging enzymes, and the capsid or surface proteins assisting the viral diffusion into the host cells (<xref rid="bib0135" ref-type="bibr">Dinesh et al., 2020</xref>). The current treatment regimen for COVID-19 includes drugs such as remdesivir, chloroquine, arbidol, favipiravir, anti-inflammatory drugs, anti-HIV drugs, and approaches such as interferon therapy, and monoclonal antibodies (<xref rid="bib0135" ref-type="bibr">Dinesh et al., 2020</xref>; <xref rid="bib0140" ref-type="bibr">Dong et al., 2020</xref>). However, there are no specific and completely effective medications against SARS-CoV-2. Although vaccine development against SARS-CoV-2 has been initiated, they are not available yet at the global level. Therefore, researchers are exploring the pool of natural and chemicals compounds that could inhibit the major proteases of the virus or downregulate the rate of propagation of the SARS-CoV-2 virus in the cells.</p><sec id="sec0040"><label>4.1</label><title>Current ongoing trials</title><p id="par0140">Different research institutes and companies worldwide have been working on clinical trials to repurpose existing drugs as well as to develop vaccines and drugs to combat the fast spreading and fatal SARS-CoV-2 (<xref rid="bib0375" ref-type="bibr">Rudra et al., 2017</xref>). For repurposing the existing drugs, randomized controlled trials (RCTs) are being undertaken by various biotechnological companies and research organizations such as National Institutes of Health (NIH), USA to identify disease specific drugs. Clinical trials are underway for major drugs that have the potential to treat COVID-19. Research on traditional medicine is also being undertaken to utilize them in the treatment of COVID-19. Plants provide a natural source of anti-viral inhibitors that can be extended for treatment of diseases caused by SARS-CoV-2. Hence, by repurposing the compounds and extracts from medicinal plants, more innovative and effective drug options can be unveiled for eliminating this viral transmission.</p></sec></sec><sec id="sec0045"><label>5</label><title>Plants with antiviral properties for the treatment of SARS diseases</title><p id="par0145">The Earth is a hub of more than 500,000 plant species, of which 10 % are utilized as food source and 10&#x02013;15 % as source of drugs (<xref rid="bib0040" ref-type="bibr">Borris, 1996</xref>). Since ancient times, phytomedicine of ethnic communities used to be the basic method of treatment in China (<xref rid="bib0070" ref-type="bibr">Chang and But, 2014</xref>), India (<xref rid="bib0125" ref-type="bibr">Dev, 1999</xref>), Africa and many other countries (<xref rid="bib0395" ref-type="bibr">Schultes and Raffauf, 1990</xref>). Globally, a major proportion of the world&#x02019;s populations rely on plant-based medications for primary health care and phytocompounds as ingredients of drugs (<xref rid="bib0165" ref-type="bibr">Farnsworth, 1990</xref>).</p><p id="par0150">Plants can serve as a wide source of viral protein inhibitors for the treatment of SARS. Plants produce a wide array of secondary metabolites that can possess inhibitory effect on the enzymes, proteins and the propagation of viruses. Secondary metabolites are expressed in response to biotic and abiotic stresses. Some examples include plant active compounds such as flavonoids, carotenoids, and diarylheptanoids. Over centuries, medicinal herbs have been used as a treatment and preventive strategy for several diseases, including respiratory viral infections (<xref rid="bib0350" ref-type="bibr">Park et al., 2016</xref>; <xref rid="bib0265" ref-type="bibr">Kiran et al., 2020</xref>; <xref rid="bib0430" ref-type="bibr">ul Qamar et al., 2020</xref>,). The benefit of using these herbs in viral respiratory infections is due to their immune stimulating and inflammation modulating effects to manage the immune system. Although numerous studies have focused on the SARS-CoV and MERS-CoV, there are few studies on cure for COVID-19 disease, which are limited to <italic>in silico</italic> studies of the phytocompounds (<xref rid="bib0315" ref-type="bibr">Mohammadi and Shaghaghi, 2020</xref>; <xref rid="bib0430" ref-type="bibr">ul Qamar et al., 2020</xref>).</p><sec id="sec0050"><label>5.1</label><title>Antiviral activity of phytocompounds against SARS-CoV, MERS-CoV and SARS-CoV-2</title><p id="par0155">Natural medicine is a valuable field of research to extract and establish curative properties. However, limited number of phytochemicals have been systematically reported for their therapeutic potential (<xref rid="bib0115" ref-type="bibr">De Clercq, 2005</xref>; <xref rid="bib0220" ref-type="bibr">Hostettmann et al., 2000</xref>). The antiviral properties of phytocompounds on SARS-CoV, MERS-CoV and SARS-CoV-2 are summarized below (<xref rid="tbl0005" ref-type="table">Table 1</xref>
):<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>List of medicinal plants, their habitat, target virus, the constituent antiviral phytocompounds, their classification, and mode of action (if reported) against coronaviruses.</p></caption><alt-text id="at0055">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">S No:</th><th align="left">Plant</th><th align="left">Habitat/ (wild/ cultivated)</th><th align="left">Virus</th><th align="left">Phyto-Compounds</th><th align="left">Classification</th><th align="left">Mode of action</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">1.</td><td align="left"><italic>Zingiber officinale</italic></td><td align="left">Asia, Hawaii, Europe (cultivated)</td><td align="left">SARS- CoV-2</td><td align="left">6-gingerol</td><td align="left">Phenolics</td><td align="left"><italic>In silico</italic> binding affinity to 5R7Y protease</td><td align="left"><xref rid="bib0365" ref-type="bibr">Rathinavel et al. (2020</xref>)</td></tr><tr><td align="left">2.</td><td align="left"><italic>Psorothamnus arborescens</italic></td><td align="left">Southwestern North America, desert and dry mountainous habitats (wild)</td><td align="left">SARS- CoV-2</td><td align="left">5,7,3&#x02032;,4&#x02032;-tetrahydroxy-2&#x02032;-(3,3-dimethylallyl) isoflavone</td><td align="left">Flavonoids</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0430" ref-type="bibr">ul Qamar et al. (2020</xref>)</td></tr><tr><td align="left">3.</td><td align="left"><italic>Lycoris radiata (Stem cortex)</italic></td><td align="left">China, Korea, Nepal, Japan, United States (cultivated)</td><td align="left">SARS- CoV</td><td align="left">Lycorine</td><td align="left">Alkaloids</td><td align="left">Inhibition of virus replication and cellular entry</td><td align="left"><xref rid="bib0275" ref-type="bibr">Li et al. (2005</xref>)</td></tr><tr><td align="left">4.</td><td align="left">a) <italic>Gentiana scabra (dried rhizome)</italic><break/>b) <italic>Dioscorea batatas (tuber)</italic><break/>c) <italic>Cassia tora (dried seed)</italic><break/>(d) <italic>Taxillus chinensis (leaf)</italic></td><td align="left">United States and Japan<break/>(cultivated)<break/>Found in an apparently wild situation in valleys and on the slopes of hills in China, sunny slopes<break/>(wild)<break/>Central America<break/>(wild)<break/>Cambodia, Indonesia, Laos, Malaysia, Philippines, Thailand, Vietnam<break/>(wild+cultivated)</td><td align="left">SARS-CoV</td><td align="left">-------</td><td align="left">-----------</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0470" ref-type="bibr">Wen et al. (2011</xref>)</td></tr><tr><td align="left">5.</td><td align="left"><italic>Glycyrrhiza glabra</italic></td><td align="left">Central and South-Western Asia, as well as to the Mediterranean region (wild)</td><td align="left">SARS-CoV</td><td align="left">Glycyrrhizin</td><td align="left">Saponin</td><td align="left">Inhibition of virus replication and cellular entry</td><td align="left"><xref rid="bib0175" ref-type="bibr">Fiore et al. (2008</xref>)</td></tr><tr><td align="left">6.</td><td align="left">a) <italic>Zingiber officinale</italic><break/>b) <italic>Piper longum</italic> L.<break/>c) <italic>Syzygium aromaticum</italic><break/>d) <italic>Tragia involucrata L</italic><break/>e) <italic>Anacyclus pyrethrum</italic><break/>f) <italic>Andrographis paniculata</italic><break/>g) <italic>Hygrophila auriculata</italic><break/>h) <italic>Terminalia chebula</italic><break/>i) <italic>Justicia adhatoda L.</italic><break/>j) <italic>Plectranthus amboinicus</italic><break/>k) <italic>Saussurea lappa</italic><break/>l) <italic>Tinospora cordifolia</italic><break/>m) <italic>Clerodendrum serratum</italic><break/>n) <italic>Sida acuta Burm. f.</italic><break/>o) <italic>Cypreus rotundus L</italic></td><td align="left">Asia, Europe, India<break/>(cultivated)<break/>India, Malaysia, Nepal, Sri Lanka and Vietnam<break/>(wild)<break/>Indonesia, India, Pakistan, Sri Lanka, Comoro Islands, Madagascar, Seychelles, and Tanzania (cultivated)<break/>Outer Himalayan ranges eastwards to Assam; southwards to Travancore, throughout warmer regions of India<break/>(wild)<break/>North Africa, Mediterranean region, Himalayas, North India, the Levant and in certain regions in the Arabian peninsula<break/>(wild+cultivated)<break/>India and Sri Lanka (wild+cultivated)<break/>Tropical Asia and Africa, India, Sri Lanka (cultivated)<break/>India and China (Yunnan), Sri Lanka, Malaysia, and Vietnam<break/>(wild)<break/>Indian subcontinent (Assam, Bangladesh, India, Nepal<break/>and Sri Lanka), Laos and Myanmar(wild)<break/>Southern and Eastern Africa, from South Africa (KwaZulu-Natal) and Swaziland to Angola and Mozambique and north to Kenya and Tanzania, India and Southeast Asia- (cultivated)<break/>North Asia- Kashmir and neighboring Himalaya region and also in Garhwal of Uttar Pradesh (wild)<break/>Indigenous to tropical regions of the Indian subcontinent<break/>(wild)<break/>Tropical and sub-tropical parts particularly in Bengal, Odisha and peninsular India<break/>(cultivated)<break/>Central America, northern Australia<break/>(wild)<break/>Africa, southern and central Europe to France and Austria), and southern Asia(wild)</td><td align="left">SARS-CoV-2</td><td align="left">&#x003b2;-sesquiphellandrene<break/>Piperine<break/>Eugenol;<break/>&#x003b2;-Caryophyllene<break/>Stigmosterol<break/>Squalene<break/>&#x003b3;-Sitosterol<break/>Andrograpanin;<break/>5-Hydroxy-7,8-<break/>dimethoxyflavanone<break/>Lupeol;<break/>Betulin<break/>Chebulagic acid<break/>Vasicinone<break/>Carvacrol<break/>Luteolin<break/>Tinosponone<break/>Bharangin<break/>Magnoflorine<break/>Cyperene</td><td align="left">Terpenoids<break/>Alkaloids<break/>Phenolics<break/>Terpenoids<break/>Lipids<break/>Terpenoids<break/>Lipids<break/>Terpenoids<break/>Flavonoids<break/>Terpenoids<break/>Terpenoids<break/>Phenolics<break/>Alkaloids<break/>Terpenoids<break/>Flavonoids<break/>Terpenoids<break/>Terpenoids<break/>Alkaloids<break/>Terpenoids</td><td align="left"><italic>In silico</italic> binding affinity to Spike (S) protein</td><td align="left"><xref rid="bib0265" ref-type="bibr">Kiran et al. (2020</xref>)</td></tr><tr><td align="left">7.</td><td align="left">a) <italic>Justicia adathoda L</italic><break/>b) <italic>Carica Papaya</italic><break/>c) <italic>Andrographis paniculata</italic><break/><italic>Burm</italic><break/>d) <italic>Ocimum tenuiflorum</italic><break/>e) <italic>Melia azedarach</italic></td><td align="left">Asia, Indian subcontinent (Assam, Bangladesh, India, Nepal and Sri Lanka), Laos and Myanmar(wild+ cultivated)<break/>Mexico and northern South America, Caribbean Islands, Florida, Texas, California, Hawaii, and other tropical and subtropical regions of the world<break/>(cultivated)<break/>India and other Asian countries<break/>(cultivated)<break/>Indian subcontinent, Southeast Asian tropics (cultivated)<break/>Southeast Asia and northern Australia, USA (cultivated)</td><td align="left">SARS-CoV-2</td><td align="left">Vasicine<break/>Quercetin<break/>Andrographolide<break/>Ursolic acid<break/>Meliacine</td><td align="left">Alkaloids<break/>Flavonoids<break/>Terpenoids<break/>Terpenoids<break/>-------</td><td align="left"><italic>In silico</italic> binding affinity to Spike (S) protein</td><td align="left"><xref rid="bib0265" ref-type="bibr">Kiran et al. (2020</xref>)</td></tr><tr><td align="left">8.</td><td align="left">a) <italic>Chamaecyparis obtuse</italic><break/>b) <italic>Juniperus formosana</italic><break/>c) <italic>Cryptomeria japonica</italic></td><td align="left">Central Japan in East Asia, northern hemisphere (cultivated)<break/>China (from Tibet in the west to Zhejiang in the east) and in Taiwan (cultivated)<break/>Japan, China, India<break/>(cultivated)</td><td align="left">SARS-CoV</td><td align="left">Ferruginol;<break/>Dehydroabieta-7-one;<break/>Sugiol;<break/>8&#x003b2;-hydroxyabieta-9 (11);<break/>6,7-dehydroroyleanone;<break/>Pinusolidic acid;<break/>&#x003b1;-cadinol;<break/>Hinokinin;<break/>Savinin<break/>3&#x003b2;,12-diacetoxyabieta-681,113-<break/>Tetraene;<break/>Cedrane-312-diol;<break/>Betulonic acid;<break/>Cryptojaponol;<break/>7&#x003b2;-<break/>Hydroxydeoxycryptojaponol;</td><td align="left">Terpenoids<break/>Terpenoids<break/>Terpenoids<break/>Terpenoids<break/>Terpenoids<break/>Terpenoids<break/>Phenolics<break/>Phenolics<break/>Terpenoids<break/>--------------<break/>Terpenoids<break/>Terpenoids<break/>Terpenoids</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0465" ref-type="bibr">Wen et al. (2007</xref>)</td></tr><tr><td align="left">9.</td><td align="left"><italic>Utrica dioica</italic></td><td align="left">Europe, Asia and western North Africa, it is now found worldwide, including New Zealand and North America (wild+ cultivated)</td><td align="left">SARS-CoV</td><td align="left">Lectin</td><td align="left"/><td align="left">Inhibition of Spike (S) protein</td><td align="left"><xref rid="bib0255" ref-type="bibr">Keyaerts et al. (2007</xref>); <xref rid="bib0435" ref-type="bibr">Van der Meer et al. (2007</xref>), Kumaki et al. (2011)</td></tr><tr><td align="left">9.</td><td align="left"><italic>Allium sativum</italic></td><td align="left">Central Asia and northeastern Iran (wild+cultivated)</td><td align="left">SARS-CoV-2</td><td align="left">Allyl disulfide; Allyl trisulfide</td><td align="left">Organosulfur</td><td align="left">Inhibition of ACE2 receptor</td><td align="left">Thuy et al. (2020)</td></tr><tr><td align="left">10.</td><td align="left"><italic>Angelica keiskei</italic></td><td align="left">Japan, where it is found on the Pacific Coast (wild)</td><td align="left">SARS-CoV</td><td align="left">Chalcone</td><td align="left">Flavonoids</td><td align="left">Inhibition of 3CL<sup>pro</sup> amd PL<sup>pro</sup></td><td align="left"><xref rid="bib0350" ref-type="bibr">Park et al. (2016</xref>)</td></tr><tr><td align="left">11.</td><td align="left"><italic>Betula pubescens</italic></td><td align="left">Northern Europe and northern Asia (wild)</td><td align="left">SARS-CoV</td><td align="left">Betulinic acid</td><td align="left">Terpenoids</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0465" ref-type="bibr">Wen et al. (2007</xref>)</td></tr><tr><td align="left">.12.</td><td align="left"><italic>Galla chinensis</italic></td><td align="left">Asia (China) (wild)</td><td align="left">SARS-CoV</td><td align="left">Tetra-O-galloyl &#x003b2;-<sc>d</sc>-glucose</td><td align="left">Phenolics</td><td align="left">Inhibition of S protein</td><td align="left"><xref rid="bib0510" ref-type="bibr">Yi et al. (2004</xref>)</td></tr><tr><td align="left">13.</td><td align="left"><italic>Alnus japonica</italic></td><td align="left">Japan, Korea, Taiwan, eastern China, and Russia (cultivated)</td><td align="left">SARS-CoV</td><td align="left">Hirsutenone;<break/>Hirsutanonol;<break/>Oregonin;<break/>Rubranol;<break/>Rubranoside B;<break/>Rubranoside A</td><td align="left">Diarylheptanoids/ Phenolics</td><td align="left">Inhibition of PL<sup>pro</sup></td><td align="left"><xref rid="bib0345" ref-type="bibr">Park et al. (2012</xref>)</td></tr><tr><td align="left">14.</td><td align="left"><italic>Curcuma longa Isatis</italic></td><td align="left">Southern Asia especially India (cultivated)</td><td align="left">SARS-CoV</td><td align="left">Curcumin</td><td align="left">Phenolics</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0465" ref-type="bibr">Wen et al. (2007</xref>)</td></tr><tr><td align="left">15.</td><td align="left"><italic>Camellia sinensis (Black tea)</italic></td><td align="left">East Asia, and probably in the borderlands of north Burma and southwestern China (cultivated)</td><td align="left">SARS-CoV</td><td align="left">Tannic acid;<break/>Theaflavin-3,3&#x002b9;-digallate</td><td align="left">Phenolics<break/>Phenolics</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0085" ref-type="bibr">Chen et al. (2005</xref>)</td></tr><tr><td align="left">16.</td><td align="left"><italic>Nicotiana benthamiana</italic></td><td align="left">Australia (cultivated)</td><td align="left">SARS-CoV</td><td align="left">NICTABA; Lectin</td><td align="left"/><td align="left">Viral growth inhibitor</td><td align="left"><xref rid="bib0535" ref-type="bibr">Zheng et al. (2009</xref>); <xref rid="bib0120" ref-type="bibr">Demurtas et al. (2016</xref>)</td></tr><tr><td align="left">17.</td><td align="left"><italic>Houttuynia cordata</italic></td><td align="left">Southeast Asia (cultivated)</td><td align="left">SARS-CoV</td><td align="left">&#x02013;</td><td align="left"/><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0270" ref-type="bibr">Lau et al. (2008)</xref>; <xref rid="bib0185" ref-type="bibr">Fung et al. (2011</xref>)</td></tr><tr><td align="left">18.</td><td align="left"><italic>Litchi chinensis</italic></td><td align="left">Native to the Guangdong and Fujian, India, other countries in Southeast Asia (cultivated)</td><td align="left">MERS-CoV</td><td align="left">Flavonoid</td><td align="left">Flavonoids</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left">Kim et al., 2019</td></tr><tr><td align="left">19.</td><td align="left"><italic>Rhizoma Cibotii</italic></td><td align="left">China (wild)</td><td align="left">SARS-CoV</td><td align="left">&#x02013;</td><td align="left"/><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0470" ref-type="bibr">Wen et al. (2011</xref>)</td></tr><tr><td align="left">20.</td><td align="left">Polygonum multiflorum Thunb.</td><td align="left">Central and southern China, Eastern Asia and the Russian Far East, Europe and North America (wild)</td><td align="left">SARS-CoV</td><td align="left">Emodin</td><td align="left">Phenolics</td><td align="left">Inhibition of ACE2 receptor, inhibition of S protein</td><td align="left"><xref rid="bib0215" ref-type="bibr">Ho et al. (2007</xref>)</td></tr><tr><td align="left">21.</td><td align="left"><italic>Rheum officinale</italic></td><td align="left">China (wild+cultivated)</td><td align="left">SARS-CoV</td><td align="left">Emodin</td><td align="left">Phenolics</td><td align="left">Inhibition of ACE2 receptor, inhibition of S protein</td><td align="left"><xref rid="bib0215" ref-type="bibr">Ho et al. (2007</xref>)</td></tr><tr><td align="left">22.</td><td align="left"><italic>Veronica linariifolia</italic></td><td align="left">Northern Hemisphere, though with some species from the Southern Hemisphere (cultivated)</td><td align="left">SARS-CoV</td><td align="left">Luteolin</td><td align="left">Flavonoids</td><td align="left">Inhibition of S protein</td><td align="left"><xref rid="bib0510" ref-type="bibr">Yi et al. (2004</xref>)</td></tr><tr><td align="left">23.</td><td align="left"><italic>Paulownia tomentosa</italic></td><td align="left">Central and western China, North America, Eastern USA (wild)</td><td align="left">SARS-CoV</td><td align="left">Tomentin A; Tomentin B; Tomentin C; Tomentin D; Tomentin E</td><td align="left">Flavonoids</td><td align="left">Inhibition of PL<sup>pro</sup></td><td align="left"><xref rid="bib0095" ref-type="bibr">Cho et al. (2013</xref>)</td></tr><tr><td align="left">24.</td><td align="left"><italic>Stephania cepharantha Hayata</italic></td><td align="left">Eastern and southern Asia and Australia (wild)</td><td align="left">SARS-CoV</td><td align="left">Cepharanthine</td><td align="left">Alkaloids</td><td align="left">Viral Growth inhibitor</td><td align="left"><xref rid="bib0080" ref-type="bibr">Chattopadhyay (2006</xref>)</td></tr><tr><td align="left">25.</td><td align="left"><italic>Myrica faya</italic></td><td align="left">Macaronesia (the Azores, Madeira, and the Canary Islands), western coastal mainland Portugal (cultivated)</td><td align="left">SARS-CoV</td><td align="left">Myricetin</td><td align="left">Flavonoids</td><td align="left">Inhibition of Helicase, nsp13</td><td align="left"><xref rid="bib0515" ref-type="bibr">Yu et al. (2012</xref>)</td></tr><tr><td align="left">26.</td><td align="left"><italic>Scutellaria lateriflora</italic></td><td align="left">North America (wild)</td><td align="left">SARS-CoV</td><td align="left">Scutellarein</td><td align="left">Flavonoids</td><td align="left">Inhibition of Helicase nsp13</td><td align="left"><xref rid="bib0515" ref-type="bibr">Yu et al. (2012</xref>)</td></tr><tr><td align="left">27.</td><td align="left"><italic>Isatis indigotica</italic></td><td align="left">Europe, especially in Western and Southern Europe, China England, Germany and France<break/>(wild)</td><td align="left">SARS-CoV</td><td align="left">Hesperetin;<break/>Sinigrin;<break/>Beta-sitosterol;<break/>Aloeemodin</td><td align="left">Flavonoids<break/>Glucosinolates<break/>Lipids<break/>Phenolics</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0280" ref-type="bibr">Lin et al. (2005</xref>)</td></tr><tr><td align="left">28.</td><td align="left"><italic>Torreya. nucifera</italic></td><td align="left">Southern Japan and to South Korea's Jeju Island (wild+cultivated)</td><td align="left">SARS-CoV</td><td align="left">Amentoflavone</td><td align="left">Flavonoids</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left"><xref rid="bib0380" ref-type="bibr">Ryu et al. (2010</xref>)</td></tr><tr><td align="left">29.</td><td align="left"><italic>Cinnamomum cassia</italic></td><td align="left">Southern China, South and Southeast Asia (India, Indonesia, Laos, Malaysia, Thailand, and Vietnam) (cultivated)</td><td align="left">SARS-CoV</td><td align="left">Procyanidin A2;<break/>Procyanidin B1;<break/>Cinnamtannin B1</td><td align="left">Flavonoids</td><td align="left">Viral growth inhibitor</td><td align="left"><xref rid="bib0550" ref-type="bibr">Zhuang et al. (2009</xref>)</td></tr><tr><td align="left">30.</td><td align="left"><italic>Linum usitatissimum</italic></td><td align="left">Syria, Switzerland and Germany, India, China (cultivated)</td><td align="left">MERS&#x02010;CoV</td><td align="left">Herbacetin</td><td align="left">Flavonoids</td><td align="left">Inhibition of 3CL<sup>pro</sup></td><td align="left">Kim et al., 2019</td></tr><tr><td align="left">31.</td><td align="left"><italic>Laurus nobilis</italic></td><td align="left">Mediterranean region (cultivated)</td><td align="left">SARS-CoV</td><td align="left">&#x003b2;-ocimene;<break/>1,8-cineole;<break/>&#x003b1;-pinene;<break/>&#x003b2;-pinene</td><td align="left">Terpenoids</td><td align="left">Viral Growth inhibitor</td><td align="left"><xref rid="bib0290" ref-type="bibr">Loizzo et al. (2008</xref>)</td></tr><tr><td align="left">32.</td><td align="left"><italic>Nicotiana tabacum</italic></td><td align="left">Caribbean, tropical and subtropical America(cultivated)</td><td align="left">SARS-CoV</td><td align="left">--------</td><td align="left">--------------</td><td align="left">Viral growth inhibitor</td><td align="left"><xref rid="bib0535" ref-type="bibr">Zheng et al. (2009</xref>); <xref rid="bib0445" ref-type="bibr">Wang et al. (2005</xref>); <xref rid="bib0180" ref-type="bibr">Franconi et al. (2018</xref>)</td></tr><tr><td align="left">33.</td><td align="left"><italic>Thymus vulgaris</italic></td><td align="left">Southern Europe from the western Mediterranean to southern Italy (cultivated)</td><td align="left">SARS-CoV-2</td><td align="left">Ursolic acid</td><td align="left">Terpenoids</td><td align="left"><italic>In silico</italic> binding affinity to 6LU7 and 6Y2E proteases</td><td align="left"><xref rid="bib0385" ref-type="bibr">Sampangi-Ramaiah et al. (2020</xref>)</td></tr><tr><td align="left">34.</td><td align="left"><italic>Coriandrum sativum</italic></td><td align="left">Southern Europe and Northern Africa to Southwestern Asia(wild and cultivated)</td><td align="left">SARS-CoV-2</td><td align="left">Coriandrin</td><td align="left">Phenolics</td><td align="left"><italic>In silico</italic> binding affinity to 6LU7 and 6Y2E proteases</td><td align="left"><xref rid="bib0385" ref-type="bibr">Sampangi-Ramaiah et al. (2020</xref>)</td></tr><tr><td align="left">35.</td><td align="left"><italic>Rosmarinus officinalis</italic></td><td align="left">Mediterranean region (wild and cultivated)</td><td align="left">SARS-CoV-2</td><td align="left">Rosmarinic acid</td><td align="left">Phenolics</td><td align="left"><italic>In silico</italic> binding affinity to 6LU7 and 6Y2E proteases</td><td align="left"><xref rid="bib0385" ref-type="bibr">Sampangi-Ramaiah et al. (2020</xref>)</td></tr><tr><td align="left">36.</td><td align="left"><italic>Brassica juncea</italic></td><td align="left">Northwest Eastern Island, Midway Atoll, Hawaii, USA, India (wild and cultivated)</td><td align="left">SARS-CoV-2</td><td align="left">Glucobrassicin</td><td align="left">Glucosinolates</td><td align="left"><italic>In silico</italic> binding affinity to 6LU7 and 6Y2E proteases</td><td align="left"><xref rid="bib0385" ref-type="bibr">Sampangi-Ramaiah et al. (2020</xref>)</td></tr></tbody></table></table-wrap></p><p id="par0160">Glycyrrhizin, a bioactive compound of Chinese liquorice (<italic>Glycyrrhiza uralensis</italic> Fisch), and lycorine isolated from <italic>Lycoris radiata</italic> L. showed strong anti-SARS-CoV activity (<xref rid="bib0275" ref-type="bibr">Li et al., 2005</xref>). Subsequently, <xref rid="bib0175" ref-type="bibr">Fiore et al. (2008)</xref> extracted glycyrrhizin from <italic>Glycyrrhiza glabra</italic> and reported that glycyrrhizin is a potent inhibitor of SARS-CoV virus replication, and adsorption and penetration of virus during the early steps of the replicative cycle.</p><p id="par0165">The caffeine beverages like green and black tea from <italic>Camellia sinensis</italic> have bioflavonoids with several medicinal properties. A study reported that water soluble tannic acid and theaflavin-3, 3&#x002b9;-digallate inhibit 3CL<sup>pro</sup> protease of SARS-CoV (<xref rid="bib0085" ref-type="bibr">Chen et al., 2005</xref>). Similarly, the phytocompounds namely hesperetin, sinigrin, beta-sitosterol, indigo and aloe emodin extracted from <italic>Isatis indigotica</italic> were found to have an inhibitory effect on the SARS-CoV 3CL<sup>pro</sup> (<xref rid="bib0280" ref-type="bibr">Lin et al., 2005</xref>).</p><p id="par0170">Quercetin is a flavonoid that is abundant in several plants and food products with a multitude of medicinal and pharmacological properties (<xref rid="bib0300" ref-type="bibr">Massi et al., 2017</xref>). Both quercetin and quercetin 3-&#x003b2;- galactoside possess the ability to inhibit the activity of 3CL<sup>pro</sup> protease of SARS-CoV <italic>in vitro</italic> (<xref rid="bib0090" ref-type="bibr">Chen et al., 2006</xref>).</p><p id="par0175">
<xref rid="bib0465" ref-type="bibr">Wen et al. (2007)</xref> screened 221 phytocompounds isolated from <italic>Chamaecyparis obtuse, Juniperus formosana</italic> and <italic>Cryptomeria japonica</italic> against SARS-CoV and found that certain abietane type di-terpenoids and lignoids have best anti-viral effects. Similarly, bioactive compounds isolated from six herbal extracts namely, <italic>Gentiana scabra</italic> (dried rhizome), <italic>Dioscorea batatas</italic> (tuber), <italic>Cassia tora</italic> (dried seed), <italic>Taxillus chinensis</italic> (leaf), and <italic>Cibotium barometz</italic> (dried rhizome) exhibited anti-SARS-CoV activity in a cell-based assay on infected Vero E6 cells at concentrations between 25 and 200 &#x003bc;g/mL (<xref rid="bib0470" ref-type="bibr">Wen et al., 2011</xref>). Several independent studies have shown that the compounds such as curcumin, caffeic acid, chalcones, cinnamic acid and betulinic acid isolated from different medicinal plants are potent inhibitors of 3CL<sup>pro</sup> protease of SARS-CoV (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Similarly, <xref rid="bib0245" ref-type="bibr">Jo et al. (2019)</xref> showed that flavonoids of <italic>Litchi chinensis</italic> and herbacetin isolated and <italic>Linum usitatissimum</italic> showed inhibition of 3CL<sup>pro</sup> in MERS-CoV.</p><p id="par0180">
<italic>Urtica dioica</italic> (Stinging nettle) has been used in different countries as traditional medicine for years owing to its therapeutic effects on cardiovascular, immune, nervous and digestive systems (<xref rid="bib0130" ref-type="bibr">Dhouibi et al., 2020</xref>). Interestingly, lectins extracted from <italic>Nicotiana tabacum</italic> (tobacco agglutinin; NICTABA), <italic>Nicotiana benthamiana</italic>, and <italic>Urtica dioica</italic> exhibit strong inhibitory potential against proliferation of the SARS-CoV (<xref rid="bib0255" ref-type="bibr">Keyaerts et al., 2007</xref>; <xref rid="bib0535" ref-type="bibr">Zheng et al., 2009</xref>; <xref rid="bib0120" ref-type="bibr">Demurtas et al., 2016</xref>). <xref rid="bib0275" ref-type="bibr">Li et al. (2005)</xref> showed that extracts of <italic>Lycoris radiata</italic> possess anti-SARS-CoV activity with a significantly lower dose of effectiveness (about 2.1&#x02013;2.4 u g/ml). The antiviral activity of the extracts was attributed to the presence of lycorine in <italic>L. radiata</italic> (<xref rid="bib0275" ref-type="bibr">Li et al., 2005</xref>).</p><p id="par0185">Phytocompounds targeting the second major protease PL<sup>pro</sup> include flavonoids (tomentins) from <italic>Paulownia tomentosa</italic> (<xref rid="bib0095" ref-type="bibr">Cho et al., 2013</xref>), chalcones from <italic>Angelica keiskei</italic> (<xref rid="bib0350" ref-type="bibr">Park et al., 2016</xref>), and diarylheptanoids extracted from <italic>Alnus japonica</italic> (<xref rid="bib0345" ref-type="bibr">Park et al., 2012</xref>), which were reported as potent inhibitors of PL<sup>pro</sup> of SARS-CoV (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>
).<fig id="fig0025"><label>Fig. 5</label><caption><p><bold>Summary of phytocompounds and their mode of action on coronaviruses.</bold> The targets of different phytocompounds is depicted as follows: <bold>a.</bold> Emodin, allyl disulfide, allyl trisulfide, and tetra-O-galloyl &#x003b2;-<sc>d</sc>-glucose inhibit ACE2 receptor binding to spike protein; <bold>b.</bold> Ferruginol, 3&#x003b2;,12-diacetoxyabieta-681,113- tetraene, and cryptojaponol inhibit virus replication; <bold>c.</bold> Flavonoids, caffeic acid, cinnamic acid, herbacetin, and hesperetin, and ursolic acid inhibit 3CL<sup>pro</sup>; <bold>d.</bold> Flavonoids, chalcones, and diarylheptanoids inhibit PL<sup>pro</sup>; <bold>e.</bold> Tetra-O-galloyl &#x003b2;-<sc>d</sc>-glucose, luteolin, terpenoids, carotenoids, ursolic acid and phytosterols target coronavirus spike protein; <bold>f.</bold> Quercetin and glycyrrhizin inhibit the cellular entry of SARS-CoV. The figure was made with the help of Biorender.com.</p></caption><alt-text id="at0045">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p><p id="par0190">An alternative way to block the activity of the SARS-CoV is to target the spike protein (S) of SARS-CoV S proteins or blocking the human ACE2 receptor. <xref rid="bib0510" ref-type="bibr">Yi et al. (2004)</xref> reported that tetra-O-galloyl &#x003b2;-<sc>d</sc>-glucose from <italic>Galla chinensis</italic> and luteolin from <italic>Veronica linariifolia</italic> exhibit strong binding affinity to spike (S) protein of SARS-CoV. Emodin (1,3,8-trihydroxy-6-methylanthraquinone), rhein (1,8-dihydroxy-3-carboxyl-910-anthraquinone), and chrysin (5,7-dihydroxyflavone) are produced in high levels in plants of genus Rheum and Polygonum; these compounds were responsible for blocking the binding of S protein in SARS-CoV to ACE2 (<xref rid="bib0215" ref-type="bibr">Ho et al., 2007</xref>; <xref rid="fig0025" ref-type="fig">Fig. 5</xref>). Emodin blocked the binding of S protein to ACE2 in a dose-dependent manner (<xref rid="bib0215" ref-type="bibr">Ho et al., 2007</xref>).</p></sec><sec id="sec0055"><label>5.2</label><title><italic>In silico</italic> studies on antiviral activity of phytocompounds against SARS-CoV-2</title><p id="par0195">Owing to the recent occurrence of COVID-19 pandemic and advances in virtual tools and databases available for drug screening, several research groups worldwide have reported <italic>in silico</italic> screening of phytocompounds reported for activity against SARS-CoV and other viral diseases.</p><p id="par0200">
<italic>Zingiber officinale</italic> (ginger) is an herbaceous plant native to South Asia belonging to the Zingiberaceae family and has been used in various countries as traditional medicine for years. The phytocompounds of ginger have been screened for binding the proteins of SARS-CoV-2 (<xref rid="bib0365" ref-type="bibr">Rathinavel et al., 2020</xref>). The phytocompound 6-gingerol showed the highest binding affinity (-15.7591 kJ/mol) with 5R7Y SARS-CoV-2 main protease, which is essential for replication and propagation of SARS-CoV-2 (<xref rid="bib0365" ref-type="bibr">Rathinavel et al., 2020</xref>). Moreover, 6-gingerol possesses excellent drug likeliness with zero violations and very good pharmacokinetic properties, indicating its potential for treating COVID-19.</p><p id="par0205">Organosulfur compounds are found in the plants of the Allium genus such as onions (<italic>e.g. Allium cepa</italic>), and garlic (<italic>Allium sativum</italic>). In a recent <italic>in silico</italic> study, the organosulfur materials such as allyl disulfide and allyl trisulfide from <italic>Allium sativum</italic> showed significant potential in binding to human ACE2, the target of SARS-CoV-2 (Thuy et al., 2020).</p><p id="par0210">In another study <xref rid="bib0430" ref-type="bibr">ul Qamar et al. (2020)</xref> screened the Chinese medicinal plants library of 32,297 phytocompounds for potential binding with 3CL<sup>pro</sup> of SARS-CoV-2 generated by homology modeling. The isoflavone namely 5,7,3&#x02032;,4&#x02032;-tetrahydroxy-2&#x02032;-(3,3-dimethylallyl) isoflavone extracted from <italic>Psorothamnus arborescens</italic> showed the highest binding affinity with 3CL<sup>pro</sup> of SARS-CoV-2 (<xref rid="tbl0005" ref-type="table">Table 1</xref>; <xref rid="bib0430" ref-type="bibr">ul Qamar et al., 2020</xref>).</p><p id="par0215">
<xref rid="bib0385" ref-type="bibr">Sampangi-Ramaiah et al. (2020)</xref> explored the <italic>in-silico</italic> binding of 27 phytocompounds (present in spices and condiments used in Indian and other cuisines) to SARS-CoV-2 6LU7 protease (3CL<sup>pro</sup>) and 6Y2E protease, both of which are required for viral replication. Out of the 27 compounds, 15 showed binding affinity above threshold values for both the proteases. The key compounds with high binding affinity to 6LU7 and 6Y2E proteases include coriandrin (component of the essential oil of <italic>Coriandrum sativum</italic> widely in Indian cuisines across both north and south India), ursolic acid of <italic>Thymus vulgaris</italic>, rosmarinic acid of <italic>Rosmarinus officinalis</italic> and glucobrassicin of <italic>Brassica juncea</italic> (<xref rid="bib0385" ref-type="bibr">Sampangi-Ramaiah et al., 2020</xref>).</p><p id="par0220">Siddha medicine is widely used in Southern India, which prescribes a concoction called Kabasura kudineer chooranam for cold, cough, and fever (<xref rid="bib0265" ref-type="bibr">Kiran et al., 2020</xref>). Molecular docking studies were performed for 32 phytochemical constituents of herbs present in Kabasura kudineer chooranam and 05 phytochemical constituents of herbal formulation named JACOM against spike protein (S) of SARS-CoV-2 (PDB ID: 6VSB) to observe the molecular interactions between target protein and ligands. All the phytochemical analogs were successfully docked with S protein of SARS-CoV-2 (<xref rid="bib0265" ref-type="bibr">Kiran et al., 2020</xref>; <xref rid="tbl0005" ref-type="table">Table 1</xref>).</p><p id="par0225">Recently, <xref rid="bib0370" ref-type="bibr">Rolta et al. (2020)</xref> reported molecular docking studies of 100 major phytocompounds of ten selected medicinal plants (<italic>Rheum emodi</italic>, <italic>Thymus serpyllum</italic>, <italic>Cymbopogon citratus</italic>, <italic>Moringa oleifera</italic>, <italic>Thalictrum foliolosum</italic>, <italic>Berberis aristata</italic>, <italic>Piper nigrum</italic>, <italic>Allium sativum</italic>, <italic>Myristica fragrans</italic> and <italic>Zanthoxylum armatum</italic>) for interaction with RNA binding domain (N-terminal Domain/ NTD; PDB 6VYO) of nucleocapsid phosphoprotein of SARS-CoV-2. The molecular docking study revealed that five phytocompounds namely emodin, anthrarufin, alizarine, aloe- emodin and dantron of <italic>Rheum emodi</italic> showed effective binding affinity and pharmacokinetic properties with NTD of RNA binding domain of nucleocapsid phosphoprotein of SARS- CoV-2 (<xref rid="bib0370" ref-type="bibr">Rolta et al., 2020</xref>).</p><p id="par0230">Based on the literature reviewed here, a total of 70 phytocompounds belonging to 8 classes from 62 different medicinal plants have been reported for anti-viral activities against coronaviruses, with focus on SARS-CoV (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>
; <xref rid="tbl0005" ref-type="table">Table 1</xref>). Most of these compounds have been used for treating other ailments in humans, revealing their multi-dimensional pharmacological properties. Analysis of the targets and mechanism of action of the phytocompounds indicates a broad spectrum of targets on both coronaviruses and the host receptors (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>). These include blocking of ACE2 receptor binding by spike protein, inhibition of viral proteases, inhibition of viral replication, targeting coronavirus spike protein, and blocking viral entry into host (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>; <xref rid="tbl0005" ref-type="table">Table 1</xref>). With ongoing research for COVID-19 therapeutics, the list of anti-viral phytocompounds is certainly dynamic with more anticipated updates.<fig id="fig0030"><label>Fig. 6</label><caption><p><bold>Structure of various classes of phytocompounds with anti-viral potential against coronaviruses studied by <italic>in vitro</italic>, <italic>in vivo</italic>, and <italic>in silico</italic> approaches.</bold> The PubChem CID of each compound is indicated in parenthesis. <bold>A:</bold> Alkaloids; <bold>B:</bold> Terpenoids; <bold>C:</bold> Flavonoids; <bold>D:</bold> Phenolics; <bold>E:</bold> phytosterols; <bold>F:</bold> Glucosinalates; <bold>G:</bold> Organosulfur compounds; <bold>H:</bold> Saponins (Source: <xref rid="tbl0005" ref-type="table">Table 1</xref>). Structures were obtained from pubchem.ncbi.nlm.nih.gov.</p></caption><alt-text id="at0050">Fig. 6</alt-text><graphic xlink:href="gr6a_lrg"/><graphic xlink:href="gr6b_lrg"/></fig></p></sec></sec><sec id="sec0060"><label>6</label><title>Conclusions</title><p id="par0235">Over the past few decades, there has been a huge demand to decipher the root of coronavirus infections not only in animals but also in humans. As a complementary approach, the search for new antiviral drugs of natural origin has gained momentum. Currently, COVID-19 has emerged as the most intense and petrifying viral infectious disease all over the world to be handled by the human race.</p><p id="par0240">Based on the high degree of homology of the genome (&#x0003e; 96 %) and the receptors of SARS-CoV and SARS-CoV-2, this review was attempted to summarize the plant species and their bioactive compounds with anti-viral potential against coronaviruses, which can be used as anti-SARS-CoV-2 agents. The literature review suggested more than 70 compounds from 62 plant species with anti-viral activity against coronaviruses that might exhibit treatment potential for COVID-19 disease. Several of these anti-viral activities have been predicted from studies on molecular docking of bioactive compounds of different medicinal plants with proteases and spike protein of</p><p id="par0245">SARS-CoV-2. Moreover, the anti-viral phytocompounds identified from <italic>in-silico</italic> studies also showed good drug-likeliness properties. Thus, the phytocompounds identified from <italic>in-silico</italic> studies can be validated by <italic>in vitro, in vivo</italic> and clinical studies against SARS-CoV-2. To assure public safety and control of infection in the event of a re-emergence of COVID-19, effective anti-SARS-CoV agents and treatments are highly desirable and imminent in the immediate and near future. The findings of this review will provide a reservoir of natural compounds for researchers world-wide focusing on drug discovery for COVID-19. The literature on anti-viral potential of phytocompounds will also pave way for experimental affirmation of several traditional and natural medicine in use for centuries in several sections of the world.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0250">The authors report no declarations of interest.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Akram</surname><given-names>M.</given-names></name><name><surname>Tahir</surname><given-names>I.M.</given-names></name><name><surname>Shah</surname><given-names>S.M.A.</given-names></name><name><surname>Mahmood</surname><given-names>Z.</given-names></name><name><surname>Altaf</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>K.</given-names></name><name><surname>Mehboob</surname><given-names>H.</given-names></name></person-group><article-title>Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review</article-title><source>Phytother. Res.</source><volume>32</volume><issue>5</issue><year>2018</year><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">29356205</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="book" id="sbref0010"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Bartlam</surname><given-names>M.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><chapter-title>Coronavirus main proteinase: target for antiviral drug therapy</chapter-title><source>Coronaviruses With Special Emphasis on First Insights Concerning SARS</source><year>2005</year><publisher-name>Birkh&#x000e4;user Basel</publisher-name><fpage>173</fpage><lpage>199</lpage></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>B&#x000e1;ez-Santos</surname><given-names>Y.M.</given-names></name><name><surname>John</surname><given-names>S.E.S.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name></person-group><article-title>The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds</article-title><source>Antiviral Res.</source><volume>115</volume><year>2015</year><fpage>21</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">25554382</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Balachandar</surname><given-names>V.</given-names></name><name><surname>Mahalaxmi</surname><given-names>I.</given-names></name><name><surname>Kaavya</surname><given-names>J.</given-names></name><name><surname>Vivekanandhan</surname><given-names>G.</given-names></name><name><surname>Ajithkumar</surname><given-names>S.</given-names></name><name><surname>Arul</surname><given-names>N.</given-names></name><name><surname>Devi</surname><given-names>S.M.</given-names></name></person-group><article-title>COVID-19: emerging protective measures</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>24</volume><issue>6</issue><year>2020</year><fpage>3422</fpage><lpage>3425</lpage><pub-id pub-id-type="pmid">32271461</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Banegas</surname><given-names>A.J.</given-names></name><name><surname>Cer&#x000f3;n-Carrasco</surname><given-names>J.P.</given-names></name><name><surname>P&#x000e9;rez-S&#x000e1;nchez</surname><given-names>H.</given-names></name></person-group><article-title>A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data</article-title><source>Future Med. Chem.</source><volume>10</volume><issue>22</issue><year>2018</year><fpage>2641</fpage><lpage>2658</lpage><pub-id pub-id-type="pmid">30499744</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>B&#x000e1;rcena</surname><given-names>M.</given-names></name><name><surname>Oostergetel</surname><given-names>G.T.</given-names></name><name><surname>Bartelink</surname><given-names>W.</given-names></name><name><surname>Faas</surname><given-names>F.G.</given-names></name><name><surname>Verkleij</surname><given-names>A.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name><name><surname>Bosch</surname><given-names>B.J.</given-names></name></person-group><article-title>Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>106</volume><issue>2</issue><year>2009</year><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">19124777</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Barreca</surname><given-names>D.</given-names></name><name><surname>Gattuso</surname><given-names>G.</given-names></name><name><surname>Bellocco</surname><given-names>E.</given-names></name><name><surname>Calderaro</surname><given-names>A.</given-names></name><name><surname>Trombetta</surname><given-names>D.</given-names></name><name><surname>Smeriglio</surname><given-names>A.</given-names></name><name><surname>Nabavi</surname><given-names>S.M.</given-names></name></person-group><article-title>Flavanones: Citrus phytochemical with health&#x02010;promoting properties</article-title><source>BioFactors</source><volume>43</volume><issue>4</issue><year>2017</year><fpage>495</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">28497905</pub-id></element-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Borris</surname><given-names>R.P.</given-names></name></person-group><article-title>Natural products research: perspectives from a major pharmaceutical company</article-title><source>J. Ethnopharmacol.</source><volume>51</volume><issue>1&#x02013;3</issue><year>1996</year><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">9213624</pub-id></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>Van der Zee</surname><given-names>R.</given-names></name><name><surname>De Haan</surname><given-names>C.A.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name></person-group><article-title>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</article-title><source>J. Virol.</source><volume>77</volume><issue>16</issue><year>2003</year><fpage>8801</fpage><lpage>8811</lpage><pub-id pub-id-type="pmid">12885899</pub-id></element-citation></ref><ref id="bib0050"><element-citation publication-type="book" id="sbref0050"><person-group person-group-type="author"><name><surname>Cascella</surname><given-names>M.</given-names></name><name><surname>Rajnik</surname><given-names>M.</given-names></name><name><surname>Cuomo</surname><given-names>A.</given-names></name><name><surname>Dulebohn</surname><given-names>S.C.</given-names></name><name><surname>Di Napoli</surname><given-names>R.</given-names></name></person-group><chapter-title>Features, evaluation and treatment coronavirus (COVID-19)</chapter-title><source>Statpearls [internet]</source><year>2020</year><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="bib0055"><element-citation publication-type="book" id="sbref0055"><person-group person-group-type="author"><name><surname>Centers for Disease Prevention and Control (CDC)</surname></name></person-group><chapter-title>Centers for Disease Prevention and Control (CDC)</chapter-title><year>2020</year><comment>(Accessed on 25 March 2020)</comment><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/index.html" id="intr0005">https://www.cdc.gov/coronavirus/2019-ncov/index.html</ext-link></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Yip</surname><given-names>C.C.Y.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name><name><surname>Tang</surname><given-names>T.H.C.</given-names></name><name><surname>Wong</surname><given-names>S.C.Y.</given-names></name><name><surname>Leung</surname><given-names>K.H.</given-names></name></person-group><article-title>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens</article-title><source>J. Clin. Microbiol.</source><volume>58</volume><issue>5</issue><year>2020</year></element-citation></ref><ref id="bib0070"><element-citation publication-type="book" id="sbref0070"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H.M.</given-names></name><name><surname>But</surname><given-names>P.P.H.</given-names></name></person-group><series>Pharmacology and Applications of Chinese Materia Medica</series><volume>Vol. I</volume><year>2014</year></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C.K.</given-names></name><name><surname>Sue</surname><given-names>S.C.</given-names></name><name><surname>Yu</surname><given-names>T.H.</given-names></name><name><surname>Hsieh</surname><given-names>C.M.</given-names></name><name><surname>Tsai</surname><given-names>C.K.</given-names></name><name><surname>Chiang</surname><given-names>Y.C.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name></person-group><article-title>Modular organization of SARS coronavirus nucleocapsid protein</article-title><source>J. Biomed. Sci.</source><volume>13</volume><issue>1</issue><year>2006</year><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16228284</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Chattopadhyay</surname><given-names>D.</given-names></name></person-group><article-title>Role and scope of ethnomedical plants in the development of antivirals</article-title><source>Pharmacologyonline</source><volume>3</volume><year>2006</year><fpage>64</fpage><lpage>72</lpage></element-citation></ref><ref id="bib0085"><element-citation publication-type="book" id="sbref0085"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.N.</given-names></name><name><surname>Lin</surname><given-names>C.P.</given-names></name><name><surname>Huang</surname><given-names>K.K.</given-names></name><name><surname>Chen</surname><given-names>W.C.</given-names></name><name><surname>Hsieh</surname><given-names>H.P.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Hsu</surname><given-names>J.T.A.</given-names></name></person-group><chapter-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3&#x02019;-digallate (TF3)</chapter-title><source>Evidence-Based Complementary and Alternative Medicine</source><year>2005</year><fpage>2</fpage></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name></person-group><article-title>Binding interaction of quercetin-3-&#x003b2;-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: structure&#x02013;activity relationship studies reveal salient pharmacophore features</article-title><source>Bioorg. Med. Chem.</source><volume>14</volume><issue>24</issue><year>2006</year><fpage>8295</fpage><lpage>8306</lpage><pub-id pub-id-type="pmid">17046271</pub-id></element-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J.K.</given-names></name><name><surname>Curtis-Long</surname><given-names>M.J.</given-names></name><name><surname>Lee</surname><given-names>K.H.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Ryu</surname><given-names>H.W.</given-names></name><name><surname>Yuk</surname><given-names>H.J.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name></person-group><article-title>Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa</article-title><source>Bioorg. Med. Chem.</source><volume>21</volume><issue>11</issue><year>2013</year><fpage>3051</fpage><lpage>3057</lpage><pub-id pub-id-type="pmid">23623680</pub-id></element-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>K.C.</given-names></name><name><surname>Wei</surname><given-names>D.Q.</given-names></name><name><surname>Zhong</surname><given-names>W.Z.</given-names></name></person-group><article-title>Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>308</volume><issue>1</issue><year>2003</year><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">12890493</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B.</given-names></name><name><surname>Valle</surname><given-names>C.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name><name><surname>Canard</surname><given-names>B.</given-names></name><name><surname>Seidah</surname><given-names>N.G.</given-names></name><name><surname>Decroly</surname><given-names>E.</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antiviral Res.</source><volume>176</volume><year>2020</year><object-id pub-id-type="publisher-id">104742</object-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Daglia</surname><given-names>M.</given-names></name></person-group><article-title>Polyphenols as antimicrobial agents</article-title><source>Curr. Opin. Biotechnol.</source><volume>23</volume><issue>2</issue><year>2012</year><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">21925860</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Recent highlights in the development of new antiviral drugs</article-title><source>Curr. Opin. Microbiol.</source><volume>8</volume><issue>5</issue><year>2005</year><fpage>552</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">16125443</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Demurtas</surname><given-names>O.C.</given-names></name><name><surname>Massa</surname><given-names>S.</given-names></name><name><surname>Illiano</surname><given-names>E.</given-names></name><name><surname>De Martinis</surname><given-names>D.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Di Bonito</surname><given-names>P.</given-names></name><name><surname>Franconi</surname><given-names>R.</given-names></name></person-group><article-title>Antigen production in plant to tackle infectious diseases flare up: the case of SARS</article-title><source>Front. Plant Sci.</source><volume>7</volume><year>2016</year><fpage>54</fpage><pub-id pub-id-type="pmid">26904039</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Dev</surname><given-names>S.</given-names></name></person-group><article-title>Ancient-modern concordance in Ayurvedic plants: some examples</article-title><source>Environ. Health Perspect.</source><volume>107</volume><issue>10</issue><year>1999</year><fpage>783</fpage><lpage>789</lpage></element-citation></ref><ref id="bib0130"><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Dhouibi</surname><given-names>R.</given-names></name><name><surname>Affes</surname><given-names>H.</given-names></name><name><surname>Salem</surname><given-names>M.B.</given-names></name><name><surname>Hammami</surname><given-names>S.</given-names></name><name><surname>Sahnoun</surname><given-names>Z.</given-names></name><name><surname>Zeghal</surname><given-names>K.M.</given-names></name><name><surname>Ksouda</surname><given-names>K.</given-names></name></person-group><article-title>Screening of pharmacological uses of Urtica dioica and others benefits</article-title><source>Prog. Biophys. Mol. Biol.</source><volume>150</volume><year>2020</year><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">31163183</pub-id></element-citation></ref><ref id="bib0135"><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Dinesh</surname><given-names>D.C.</given-names></name><name><surname>Tamilarasan</surname><given-names>S.</given-names></name><name><surname>Rajaram</surname><given-names>K.</given-names></name><name><surname>Bou&#x00159;a</surname><given-names>E.</given-names></name></person-group><article-title>Antiviral drug targets of single-stranded RNA viruses causing chronic human diseases</article-title><source>Curr. Drug Targets</source><volume>21</volume><issue>2</issue><year>2020</year><fpage>105</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">31538891</pub-id></element-citation></ref><ref id="bib0140"><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discov. Ther.</source><volume>14</volume><issue>2020</issue><year>2020</year><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">32147628</pub-id></element-citation></ref><ref id="bib0145"><element-citation publication-type="book" id="sbref0145"><person-group person-group-type="author"><name><surname>Dorigatti</surname><given-names>I.</given-names></name><name><surname>Okell</surname><given-names>L.</given-names></name><name><surname>Cori</surname><given-names>A.</given-names></name><name><surname>Imai</surname><given-names>N.</given-names></name><name><surname>Baguelin</surname><given-names>M.</given-names></name><name><surname>Bhatia</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>H.</given-names></name></person-group><chapter-title>Report 4: Severity of 2019-novel Coronavirus (nCoV)</chapter-title><year>2020</year><publisher-name>Imperial College London</publisher-name><publisher-loc>London</publisher-loc></element-citation></ref><ref id="bib0150"><element-citation publication-type="book" id="sbref0150"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>M.</given-names></name></person-group><chapter-title>What You Need to Know About Infectious Disease</chapter-title><year>2010</year></element-citation></ref><ref id="bib0155"><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Durai</surname><given-names>P.</given-names></name><name><surname>Batool</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control</article-title><source>Exp. Mol. Med.</source><volume>47</volume><issue>8</issue><year>2015</year><comment>e181-e181</comment></element-citation></ref><ref id="bib0160"><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Eweas</surname><given-names>A.F.</given-names></name><name><surname>Maghrabi</surname><given-names>I.A.</given-names></name><name><surname>Namarneh</surname><given-names>A.I.</given-names></name></person-group><article-title>Advances in molecular modeling and docking as a tool for modern drug discovery</article-title><source>Der Pharma Chemica</source><volume>6</volume><issue>6</issue><year>2014</year><fpage>211</fpage><lpage>228</lpage></element-citation></ref><ref id="bib0165"><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Farnsworth</surname><given-names>N.R.</given-names></name></person-group><article-title>The role of ethnopharmacology in drug development</article-title><source>Bioact. Compounds Plants</source><volume>154</volume><year>1990</year><fpage>2</fpage><lpage>21</lpage></element-citation></ref><ref id="bib0170"><element-citation publication-type="book" id="sbref0170"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><chapter-title>Coronaviruses: an overview of their replication and pathogenesis</chapter-title><source>Coronaviruses</source><year>2015</year><publisher-name>Humana Press</publisher-name><publisher-loc>New York, NY</publisher-loc><fpage>1</fpage><lpage>23</lpage></element-citation></ref><ref id="bib0175"><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>C.</given-names></name><name><surname>Eisenhut</surname><given-names>M.</given-names></name><name><surname>Krausse</surname><given-names>R.</given-names></name><name><surname>Ragazzi</surname><given-names>E.</given-names></name><name><surname>Pellati</surname><given-names>D.</given-names></name><name><surname>Armanini</surname><given-names>D.</given-names></name><name><surname>Bielenberg</surname><given-names>J.</given-names></name></person-group><article-title>Antiviral effects of Glycyrrhiza species</article-title><source>Phytotherapy Res.</source><volume>22</volume><issue>2</issue><year>2008</year><fpage>141</fpage><lpage>148</lpage></element-citation></ref><ref id="bib0180"><element-citation publication-type="book" id="sbref0180"><person-group person-group-type="author"><name><surname>Franconi</surname><given-names>R.</given-names></name><name><surname>Illiano</surname><given-names>E.</given-names></name><name><surname>Paolini</surname><given-names>F.</given-names></name><name><surname>Massa</surname><given-names>S.</given-names></name><name><surname>Venuti</surname><given-names>A.</given-names></name><name><surname>Demurtas</surname><given-names>O.C.</given-names></name></person-group><chapter-title>Rapid and Low-cost tools derived from plants to face Emerging/Re-emerging infectious diseases and bioterrorism agents</chapter-title><source>Defence Against Bioterrorism</source><year>2018</year><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht</publisher-loc><fpage>123</fpage><lpage>139</lpage></element-citation></ref><ref id="bib0185"><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>K.P.</given-names></name><name><surname>Leung</surname><given-names>P.C.</given-names></name><name><surname>Tsui</surname><given-names>K.W.</given-names></name><name><surname>Wan</surname><given-names>C.C.</given-names></name><name><surname>Wong</surname><given-names>K.B.</given-names></name><name><surname>Waye</surname><given-names>M.Y.</given-names></name></person-group><article-title>Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: a randomised, double-blind, placebo-controlled study</article-title><source>Hong Kong Med. J.= Xianggang yi xue za zhi</source><volume>17</volume><year>2011</year><fpage>41</fpage></element-citation></ref><ref id="bib0190"><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Gatera</surname><given-names>G.</given-names></name><name><surname>Pavarini</surname><given-names>G.</given-names></name></person-group><article-title>COVID-19: what is next for public health</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>542</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">32061313</pub-id></element-citation></ref><ref id="bib0195"><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Gomathi</surname><given-names>M.</given-names></name><name><surname>Padmapriya</surname><given-names>S.</given-names></name><name><surname>Balachandar</surname><given-names>V.</given-names></name></person-group><article-title>Drug studies on Rett syndrome: from bench to bedside</article-title><source>J. Autism Dev. Disord.</source><year>2020</year><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">31729599</pub-id></element-citation></ref><ref id="bib0200"><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name></person-group><article-title>Nidovirales: evolving the largest RNA virus genome</article-title><source>Virus Res.</source><volume>117</volume><issue>1</issue><year>2006</year><fpage>17</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16503362</pub-id></element-citation></ref><ref id="bib0205"><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>de Groot</surname><given-names>R.J.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Gulyaeva</surname><given-names>A.A.</given-names></name></person-group><article-title>The species severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat. Microbiol.</source><volume>5</volume><year>2020</year><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">32123347</pub-id></element-citation></ref><ref id="bib0210"><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>A comparison of various optimization algorithms of protein&#x02013;ligand docking programs by fitness accuracy</article-title><source>J. Mol. Model.</source><volume>20</volume><issue>7</issue><year>2014</year><fpage>2251</fpage><pub-id pub-id-type="pmid">24935106</pub-id></element-citation></ref><ref id="bib0215"><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>T.Y.</given-names></name><name><surname>Wu</surname><given-names>S.L.</given-names></name><name><surname>Chen</surname><given-names>J.C.</given-names></name><name><surname>Li</surname><given-names>C.C.</given-names></name><name><surname>Hsiang</surname><given-names>C.Y.</given-names></name></person-group><article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction</article-title><source>Antiviral Res.</source><volume>74</volume><issue>2</issue><year>2007</year><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">16730806</pub-id></element-citation></ref><ref id="bib0220"><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Hostettmann</surname><given-names>K.</given-names></name><name><surname>Marston</surname><given-names>A.</given-names></name><name><surname>Ndjoko</surname><given-names>K.</given-names></name><name><surname>Wolfender</surname><given-names>J.L.</given-names></name></person-group><article-title>The potential of African plants as a source of drugs</article-title><source>Curr. Org. Chem.</source><volume>4</volume><issue>10</issue><year>2000</year><fpage>973</fpage><lpage>1010</lpage></element-citation></ref><ref id="bib0225"><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib0230"><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>K.R.</given-names></name><name><surname>Koetzner</surname><given-names>C.A.</given-names></name><name><surname>Masters</surname><given-names>P.S.</given-names></name></person-group><article-title>Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein</article-title><source>J. Virol.</source><volume>83</volume><issue>14</issue><year>2009</year><fpage>7221</fpage><lpage>7234</lpage><pub-id pub-id-type="pmid">19420077</pub-id></element-citation></ref><ref id="bib0235"><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>K.K.</given-names></name><name><surname>Renzette</surname><given-names>N.</given-names></name><name><surname>Kowalik</surname><given-names>T.F.</given-names></name><name><surname>Jensen</surname><given-names>J.D.</given-names></name></person-group><article-title>Antiviral drug resistance as an adaptive process</article-title><source>Virus Evol.</source><volume>2</volume><issue>1</issue><year>2016</year></element-citation></ref><ref id="bib0240"><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Izaguirre</surname><given-names>G.</given-names></name></person-group><article-title>The proteolytic regulation of virus cell entry by furin and other proprotein convertases</article-title><source>Viruses</source><volume>11</volume><issue>9</issue><year>2019</year><fpage>837</fpage></element-citation></ref><ref id="bib0245"><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name></person-group><article-title>Characteristics of flavonoids as potent MERS&#x02010;CoV 3C&#x02010;like protease inhibitors</article-title><source>Chem. Biol. Drug Des.</source><volume>94</volume><issue>6</issue><year>2019</year><fpage>2023</fpage><lpage>2030</lpage><pub-id pub-id-type="pmid">31436895</pub-id></element-citation></ref><ref id="bib0250"><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>S.</given-names></name><name><surname>Ali</surname><given-names>P.S.S.</given-names></name><name><surname>Sheeza</surname><given-names>A.</given-names></name><name><surname>Hemalatha</surname><given-names>K.</given-names></name></person-group><article-title>COVID-19 (Novel Coronavirus 2019)-recent trends</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>24</volume><issue>4</issue><year>2020</year><fpage>2006</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">32141569</pub-id></element-citation></ref><ref id="bib0255"><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>Els</given-names></name><name><surname>Vijgen</surname><given-names>Leen</given-names></name><name><surname>Pannecouque</surname><given-names>Christophe</given-names></name><name><surname>Damme</surname><given-names>Els Van</given-names></name><name><surname>Peumans</surname><given-names>Willy</given-names></name><name><surname>Egberink</surname><given-names>Herman</given-names></name><name><surname>Balzarini</surname><given-names>Jan</given-names></name><name><surname>Ranst</surname><given-names>Marc Van</given-names></name></person-group><article-title>Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle</article-title><source>Antiviral Res.</source><volume>75</volume><issue>3</issue><year>2007</year><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">17428553</pub-id></element-citation></ref><ref id="bib0260"><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>Killerby</surname><given-names>M.E.</given-names></name><name><surname>Biggs</surname><given-names>H.M.</given-names></name><name><surname>Haynes</surname><given-names>A.</given-names></name><name><surname>Dahl</surname><given-names>R.M.</given-names></name><name><surname>Mustaquim</surname><given-names>D.</given-names></name><name><surname>Gerber</surname><given-names>S.I.</given-names></name><name><surname>Watson</surname><given-names>J.T.</given-names></name></person-group><article-title>Human coronavirus circulation in the United States 2014&#x02013;2017</article-title><source>J. Clin. Virol.</source><volume>101</volume><year>2018</year><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">29427907</pub-id></element-citation></ref><ref id="bib0265"><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Kiran</surname><given-names>G.</given-names></name><name><surname>Karthik</surname><given-names>L.</given-names></name><name><surname>Devi</surname><given-names>S.</given-names></name><name><surname>Sathiyarajeswaran</surname><given-names>P.</given-names></name><name><surname>Kanakavalli</surname><given-names>K.</given-names></name><name><surname>Kumar</surname><given-names>K.M.</given-names></name><name><surname>Kumar</surname><given-names>D.R.</given-names></name></person-group><article-title>In silico computational screening of kabasura kudineer-official siddha formulation and JACOM against SARS-CoV-2 spike protein</article-title><source>J. Ayurveda Integr. Med.</source><volume>S0975&#x02013;9476</volume><issue>20</issue><year>2020</year><fpage>30024</fpage><lpage>30033</lpage></element-citation></ref><ref id="bib0270"><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>K.M.</given-names></name><name><surname>Lee</surname><given-names>K.M.</given-names></name><name><surname>Koon</surname><given-names>C.M.</given-names></name><name><surname>Cheung</surname><given-names>C.S.F.</given-names></name><name><surname>Lau</surname><given-names>C.P.</given-names></name><name><surname>Ho</surname><given-names>H.M.</given-names></name></person-group><article-title>Immunomodulatory and anti-SARS activities of Houttuynia cordata</article-title><source>J. Ethnopharmacol.</source><volume>118</volume><issue>1</issue><year>2008</year><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">18479853</pub-id></element-citation></ref><ref id="bib0275"><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.Y.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>H.Q.</given-names></name><name><surname>Guo</surname><given-names>H.Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Identification of natural compounds with antiviral activities against SARS-associated coronavirus</article-title><source>Antiviral Res.</source><volume>67</volume><issue>1</issue><year>2005</year><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15885816</pub-id></element-citation></ref><ref id="bib0280"><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.W.</given-names></name><name><surname>Tsai</surname><given-names>F.J.</given-names></name><name><surname>Tsai</surname><given-names>C.H.</given-names></name><name><surname>Lai</surname><given-names>C.C.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Ho</surname><given-names>T.Y.</given-names></name><name><surname>Chao</surname><given-names>P.D.L.</given-names></name></person-group><article-title>Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds</article-title><source>Antiviral Res.</source><volume>68</volume><issue>1</issue><year>2005</year><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16115693</pub-id></element-citation></ref><ref id="bib0285"><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Loeffelholz</surname><given-names>M.J.</given-names></name><name><surname>Tang</surname><given-names>Y.W.</given-names></name></person-group><article-title>Laboratory diagnosis of emerging human coronavirus infections&#x02013;the state of the art</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>747</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">32196430</pub-id></element-citation></ref><ref id="bib0290"><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Loizzo</surname><given-names>M.R.</given-names></name><name><surname>Saab</surname><given-names>A.M.</given-names></name><name><surname>Tundis</surname><given-names>R.</given-names></name><name><surname>Statti</surname><given-names>G.A.</given-names></name><name><surname>Menichini</surname><given-names>F.</given-names></name><name><surname>Lampronti</surname><given-names>I.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name></person-group><article-title>Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species</article-title><source>Chem. Biodivers.</source><volume>5</volume><issue>3</issue><year>2008</year><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">18357554</pub-id></element-citation></ref><ref id="bib0295"><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><issue>10224</issue><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="bib0300"><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>Massi</surname><given-names>A.</given-names></name><name><surname>Bortolini</surname><given-names>O.</given-names></name><name><surname>Ragno</surname><given-names>D.</given-names></name><name><surname>Bernardi</surname><given-names>T.</given-names></name><name><surname>Sacchetti</surname><given-names>G.</given-names></name><name><surname>Tacchini</surname><given-names>M.</given-names></name><name><surname>De Risi</surname><given-names>C.</given-names></name></person-group><article-title>Research progress in the modification of quercetin leading to anticancer agents</article-title><source>Molecules</source><volume>22</volume><issue>8</issue><year>2017</year><fpage>1270</fpage></element-citation></ref><ref id="bib0305"><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P.S.</given-names></name></person-group><article-title>The molecular biology of coronaviruses</article-title><source>Adv. Virus Res.</source><volume>66</volume><year>2006</year><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">16877062</pub-id></element-citation></ref><ref id="bib0310"><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>V.D.</given-names></name><name><surname>Mitchell</surname><given-names>H.D.</given-names></name><name><surname>Cockrell</surname><given-names>A.S.</given-names></name><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Yount</surname><given-names>B.L.</given-names><suffix>Jr</suffix></name><name><surname>Graham</surname><given-names>R.L.</given-names></name></person-group><article-title>MERS-CoV accessory ORFs play key role for infection and pathogenesis</article-title><source>mBio</source><volume>8</volume><year>2017</year><fpage>e00665</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">28830941</pub-id></element-citation></ref><ref id="bib0315"><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>N.</given-names></name><name><surname>Shaghaghi</surname><given-names>N.</given-names></name></person-group><article-title>Inhibitory effect of eight secondary metabolites from conventional medicinal plants on COVID_19 virus protease by molecular docking analysis</article-title><source>Preprint</source><year>2020</year><comment>https://doi.org/10.26434/chemrxiv, 11987475, v1</comment></element-citation></ref><ref id="bib0320"><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>D.R.</given-names></name><name><surname>Geballe</surname><given-names>A.P.</given-names></name></person-group><article-title>Upstream open reading frames as regulators of mRNA translation</article-title><source>Mol. Cell. Biol.</source><volume>20</volume><issue>23</issue><year>2000</year><fpage>8635</fpage><lpage>8642</lpage><pub-id pub-id-type="pmid">11073965</pub-id></element-citation></ref><ref id="bib0325"><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Nal</surname><given-names>B.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Siu</surname><given-names>L.</given-names></name><name><surname>Tse</surname><given-names>J.</given-names></name><name><surname>Chu</surname><given-names>K.</given-names></name><name><surname>van der Werf</surname><given-names>S.</given-names></name></person-group><article-title>Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E</article-title><source>J. Gen. Virol.</source><volume>86</volume><issue>5</issue><year>2005</year><fpage>1423</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">15831954</pub-id></element-citation></ref><ref id="bib0330"><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Neiderud</surname><given-names>C.J.</given-names></name></person-group><article-title>How urbanization affects the epidemiology of emerging infectious diseases</article-title><source>Infect. Ecol. Epidemiol.</source><volume>5</volume><issue>1</issue><year>2015</year><fpage>27060</fpage><pub-id pub-id-type="pmid">26112265</pub-id></element-citation></ref><ref id="bib0335"><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>Neuman</surname><given-names>B.W.</given-names></name><name><surname>Adair</surname><given-names>B.D.</given-names></name><name><surname>Yoshioka</surname><given-names>C.</given-names></name><name><surname>Quispe</surname><given-names>J.D.</given-names></name><name><surname>Orca</surname><given-names>G.</given-names></name><name><surname>Kuhn</surname><given-names>P.</given-names></name><name><surname>Buchmeier</surname><given-names>M.J.</given-names></name></person-group><article-title>Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy</article-title><source>J. Virol.</source><volume>80</volume><issue>16</issue><year>2006</year><fpage>7918</fpage><lpage>7928</lpage><pub-id pub-id-type="pmid">16873249</pub-id></element-citation></ref><ref id="bib0340"><element-citation publication-type="book" id="sbref0340"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S.Y.</given-names></name><name><surname>Zhou</surname><given-names>S.F.</given-names></name><name><surname>Gao</surname><given-names>S.H.</given-names></name><name><surname>Yu</surname><given-names>Z.L.</given-names></name><name><surname>Zhang</surname><given-names>S.F.</given-names></name><name><surname>Tang</surname><given-names>M.K.</given-names></name></person-group><chapter-title>New perspectives on how to discover drugs from herbal medicines: CAM&#x02019;s outstanding contribution to modern therapeutics</chapter-title><source>Evidence-Based Complementary and Alternative Medicine</source><year>2013</year><fpage>2013</fpage></element-citation></ref><ref id="bib0345"><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Park</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Ryu</surname><given-names>Y.B.</given-names></name></person-group><article-title>Diarylheptanoids from <italic>Alnus japonica</italic> inhibit papain-like protease of severe acute respiratory syndrome coronavirus</article-title><source>Biol. Pharm. Bull.</source><year>2012</year><fpage>b12</fpage><lpage>00623</lpage></element-citation></ref><ref id="bib0350"><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Ko</surname><given-names>J.A.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name></person-group><article-title>Chalcones isolated from <italic>Angelica keiskei</italic> inhibit cysteine proteases of SARS-CoV</article-title><source>J. Enzyme Inhib. Med. Chem.</source><volume>31</volume><issue>1</issue><year>2016</year><fpage>23</fpage><lpage>30</lpage></element-citation></ref><ref id="bib0355"><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Severe acute respiratory syndrome</article-title><source>Nat. Med.</source><volume>10</volume><issue>12</issue><year>2004</year><fpage>S88</fpage><lpage>S97</lpage><pub-id pub-id-type="pmid">15577937</pub-id></element-citation></ref><ref id="bib0360"><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>MERS: emergence of a novel human coronavirus</article-title><source>Curr. Opin. Virol.</source><volume>5</volume><year>2014</year><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">24584035</pub-id></element-citation></ref><ref id="bib0365"><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Rathinavel</surname><given-names>T.</given-names></name><name><surname>Palanisamy</surname><given-names>M.</given-names></name><name><surname>Palanisamy</surname><given-names>S.</given-names></name><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Thangaswamy</surname><given-names>S.</given-names></name></person-group><article-title>Phytochemical 6-Gingerol- A promising Drug of choice for COVID-19</article-title><source>Int. J. Adv. Sci. Eng.</source><volume>6</volume><issue>4</issue><year>2020</year><fpage>1482</fpage><lpage>1489</lpage></element-citation></ref><ref id="bib0370"><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Rolta</surname><given-names>R.</given-names></name><name><surname>Yadav</surname><given-names>R.</given-names></name><name><surname>Salaria</surname><given-names>D.</given-names></name><name><surname>Trivedi</surname><given-names>S.</given-names></name><name><surname>Imran</surname><given-names>M.</given-names></name><name><surname>Sourirajan</surname><given-names>A.</given-names></name><name><surname>Baumler</surname><given-names>D.J.</given-names></name><name><surname>Dev</surname><given-names>K.</given-names></name></person-group><article-title><italic>In silico</italic>screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: an approach to prevent virus assembly</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1804457</pub-id><comment>Online ahead of print</comment></element-citation></ref><ref id="bib0375"><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name><surname>Rudra</surname><given-names>S.</given-names></name><name><surname>Kalra</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Joe</surname><given-names>W.</given-names></name></person-group><article-title>Utilization of alternative systems of medicine as health care services in India: evidence on AYUSH care from NSS 2014</article-title><source>PLoS One</source><volume>12</volume><issue>5</issue><year>2017</year><object-id pub-id-type="publisher-id">e0176916</object-id></element-citation></ref><ref id="bib0380"><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>Y.B.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name></person-group><article-title>Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition</article-title><source>Bioorg. Med. Chem.</source><volume>18</volume><issue>22</issue><year>2010</year><fpage>7940</fpage><lpage>7947</lpage><pub-id pub-id-type="pmid">20934345</pub-id></element-citation></ref><ref id="bib0385"><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name><surname>Sampangi-Ramaiah</surname><given-names>M.H.</given-names></name><name><surname>Vishwakarma</surname><given-names>R.</given-names></name><name><surname>Shaanker</surname><given-names>R.U.</given-names></name></person-group><article-title>Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease</article-title><source>Curr. Sci.</source><volume>118</volume><issue>7</issue><year>2020</year><fpage>1087</fpage><lpage>1092</lpage></element-citation></ref><ref id="bib0390"><element-citation publication-type="journal" id="sbref0390"><person-group person-group-type="author"><name><surname>Schoeman</surname><given-names>D.</given-names></name><name><surname>Fielding</surname><given-names>B.C.</given-names></name></person-group><article-title>Coronavirus envelope protein: current knowledge</article-title><source>Virol. J.</source><volume>16</volume><issue>1</issue><year>2019</year><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">30606229</pub-id></element-citation></ref><ref id="bib0395"><element-citation publication-type="book" id="sbref0395"><person-group person-group-type="author"><name><surname>Schultes</surname><given-names>R.E.</given-names></name><name><surname>Raffauf</surname><given-names>R.F.</given-names></name></person-group><chapter-title>The Healing Forest: Medicinal and Toxic Plants of the Northwest Amazonia</chapter-title><year>1990</year><publisher-name>Dioscorides press</publisher-name></element-citation></ref><ref id="bib0400"><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>S.A.</given-names></name><name><surname>Jain</surname><given-names>T.</given-names></name><name><surname>Sandhu</surname><given-names>G.</given-names></name><name><surname>Soni</surname><given-names>A.</given-names></name><name><surname>Jayaram</surname><given-names>B.</given-names></name></person-group><article-title>From drug target to leads-sketching a physico-chemical pathway for lead molecule design in silico</article-title><source>Front. Med. Chem. Online</source><volume>6</volume><year>2013</year><fpage>324</fpage></element-citation></ref><ref id="bib0405"><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Tan</surname><given-names>C.</given-names></name></person-group><article-title>2019 novel coronavirus (COVID-19) pneumonia with hemoptysis as the initial symptom: CT and clinical features</article-title><source>Korean J. Radiol.</source><volume>21</volume><issue>5</issue><year>2020</year><fpage>537</fpage><pub-id pub-id-type="pmid">32174057</pub-id></element-citation></ref><ref id="bib0410"><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>E.C.</given-names></name><name><surname>Blanc</surname><given-names>H.</given-names></name><name><surname>Vignuzzi</surname><given-names>M.</given-names></name><name><surname>Denison</surname><given-names>M.R.</given-names></name></person-group><article-title>Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics</article-title><source>PLoS Pathog.</source><volume>9</volume><issue>8</issue><year>2013</year><object-id pub-id-type="publisher-id">e1003565</object-id></element-citation></ref><ref id="bib0415"><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Bredenbeek</surname><given-names>P.J.</given-names></name><name><surname>Dobbe</surname><given-names>J.C.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name></person-group><article-title>Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage</article-title><source>J. Mol. Biol.</source><volume>331</volume><issue>5</issue><year>2003</year><fpage>991</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">12927536</pub-id></element-citation></ref><ref id="bib0420"><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>From SARS to MERS, thrusting coronaviruses into the spotlight</article-title><source>Viruses</source><volume>11</volume><issue>1</issue><year>2019</year><fpage>59</fpage></element-citation></ref><ref id="bib0425"><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Tapparel</surname><given-names>C.</given-names></name><name><surname>Sobo</surname><given-names>K.</given-names></name><name><surname>Constant</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Van Belle</surname><given-names>S.</given-names></name><name><surname>Kaiser</surname><given-names>L.</given-names></name></person-group><article-title>Growth and characterization of different human rhinovirus C types in three-dimensional human airway epithelia reconstituted in vitro</article-title><source>Virology</source><volume>446</volume><issue>1-2</issue><year>2013</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24074561</pub-id></element-citation></ref><ref id="bib0430"><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name><surname>ul Qamar</surname><given-names>M.T.</given-names></name><name><surname>Alqahtani</surname><given-names>S.M.</given-names></name><name><surname>Alamri</surname><given-names>M.A.</given-names></name><name><surname>Chen</surname><given-names>L.L.</given-names></name></person-group><article-title>Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants</article-title><source>J. Pharm. Anal.</source><volume>10</volume><issue>4</issue><year>2020</year><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">32296570</pub-id></element-citation></ref><ref id="bib0435"><element-citation publication-type="journal" id="sbref0435"><person-group person-group-type="author"><name><surname>Van der Meer</surname><given-names>F.J.U.M.</given-names></name><name><surname>de Haan</surname><given-names>C.A.M.</given-names></name><name><surname>Schuurman</surname><given-names>N.M.P.</given-names></name><name><surname>Haijema</surname><given-names>B.J.</given-names></name><name><surname>Verheije</surname><given-names>M.H.</given-names></name><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>Egberink</surname><given-names>H.F.</given-names></name></person-group><article-title>The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins</article-title><source>J. Antimicrob. Chemother.</source><volume>60</volume><issue>4</issue><year>2007</year><fpage>741</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">17704516</pub-id></element-citation></ref><ref id="bib0440"><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title><source>J. Virol.</source><volume>94</volume><issue>7</issue><year>2020</year></element-citation></ref><ref id="bib0445"><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>Z.</given-names></name><name><surname>Ouyang</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Chao</surname><given-names>Y.</given-names></name><name><surname>Hung</surname><given-names>T.</given-names></name></person-group><article-title>Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients</article-title><source>DNA Cell Biol.</source><volume>24</volume><issue>8</issue><year>2005</year><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">16101351</pub-id></element-citation></ref><ref id="bib0450"><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan, China</article-title><source>Jama</source><volume>323</volume><issue>11</issue><year>2020</year><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">32031570</pub-id></element-citation></ref><ref id="bib0455"><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.S.</given-names></name><name><surname>Wang</surname><given-names>Y.R.</given-names></name><name><surname>Ye</surname><given-names>D.W.</given-names></name><name><surname>Liu</surname><given-names>Q.Q.</given-names></name></person-group><article-title>A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><object-id pub-id-type="publisher-id">105948</object-id></element-citation></ref><ref id="bib0460"><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><volume>30</volume><issue>3</issue><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="bib0465"><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>C.C.</given-names></name><name><surname>Kuo</surname><given-names>Y.H.</given-names></name><name><surname>Jan</surname><given-names>J.T.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Wang</surname><given-names>S.Y.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name></person-group><article-title>Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus</article-title><source>J. Med. Chem.</source><volume>50</volume><issue>17</issue><year>2007</year><fpage>4087</fpage><lpage>4095</lpage><pub-id pub-id-type="pmid">17663539</pub-id></element-citation></ref><ref id="bib0470"><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>C.C.</given-names></name><name><surname>Shyur</surname><given-names>L.F.</given-names></name><name><surname>Jan</surname><given-names>J.T.</given-names></name><name><surname>Liang</surname><given-names>P.H.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Arulselvan</surname><given-names>P.</given-names></name></person-group><article-title>Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication</article-title><source>J. Tradit. Complement. Med.</source><volume>1</volume><issue>1</issue><year>2011</year><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">24716104</pub-id></element-citation></ref><ref id="bib0475"><element-citation publication-type="book" id="sbref0475"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><chapter-title>Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</chapter-title><comment>(Accessed 1/4/2020)</comment><year>2020</year><publisher-name>World Health Organization</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intr0010">https://www.who.int/emergencies/mers-cov/en/</ext-link></element-citation></ref><ref id="bib0480"><element-citation publication-type="journal" id="sbref0480"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A.K.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Sneed</surname><given-names>L.W.</given-names></name><name><surname>Collisson</surname><given-names>E.W.</given-names></name></person-group><article-title>Analysis of a hypervariable region in the 3&#x02019;non-coding end of the infectious bronchitis virus genome</article-title><source>Virus Res.</source><volume>28</volume><issue>1</issue><year>1993</year><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">8388141</pub-id></element-citation></ref><ref id="bib0485"><element-citation publication-type="book" id="sbref0485"><person-group person-group-type="author"><name><surname>World Health Organization (WHO)</surname></name></person-group><chapter-title>Laboratory testing of 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases</chapter-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/" id="intr0015">https://apps.who.int/iris/handle/10665/</ext-link></element-citation></ref><ref id="bib0490"><element-citation publication-type="book" id="sbref0490"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>M.L.</given-names></name></person-group><chapter-title>Complete Genome Characterisation of a Novel Coronavirus Associated With Severe Human Respiratory Disease in Wuhan, China</chapter-title><comment>bioRxiv</comment><year>2020</year></element-citation></ref><ref id="bib0495"><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.G.</given-names></name><name><surname>Yuan</surname><given-names>M.L.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bib0500"><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Teng</surname><given-names>T.</given-names></name><name><surname>Abdalla</surname><given-names>A.E.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name></person-group><article-title>Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV</article-title><source>Viruses</source><volume>12</volume><issue>2</issue><year>2020</year><fpage>244</fpage></element-citation></ref><ref id="bib0505"><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name></person-group><article-title>Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2020</year><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="bib0510"><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yuan</surname><given-names>K.</given-names></name><name><surname>Qu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells</article-title><source>J. Virol.</source><volume>78</volume><issue>20</issue><year>2004</year><fpage>11334</fpage><lpage>11339</lpage><pub-id pub-id-type="pmid">15452254</pub-id></element-citation></ref><ref id="bib0515"><element-citation publication-type="journal" id="sbref0515"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Chin</surname><given-names>Y.W.</given-names></name><name><surname>Jee</surname><given-names>J.G.</given-names></name><name><surname>Jeong</surname><given-names>Y.J.</given-names></name></person-group><article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>22</volume><issue>12</issue><year>2012</year><fpage>4049</fpage><lpage>4054</lpage><pub-id pub-id-type="pmid">22578462</pub-id></element-citation></ref><ref id="bib0520"><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>Van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><volume>367</volume><issue>19</issue><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib0525"><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.W.</given-names></name><name><surname>Yap</surname><given-names>Y.L.</given-names></name></person-group><article-title>Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs</article-title><source>Bioorg. Med. Chem.</source><volume>12</volume><issue>10</issue><year>2004</year><fpage>2517</fpage><lpage>2521</lpage><pub-id pub-id-type="pmid">15110833</pub-id></element-citation></ref><ref id="bib0530"><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>N.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target</article-title><source>Intensive Care Med.</source><volume>46</volume><issue>4</issue><year>2020</year><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">32125455</pub-id></element-citation></ref><ref id="bib0535"><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>N.</given-names></name><name><surname>Xia</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Duan</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>Q.</given-names></name></person-group><article-title>Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice</article-title><source>Vaccine</source><volume>27</volume><issue>36</issue><year>2009</year><fpage>5001</fpage><lpage>5007</lpage><pub-id pub-id-type="pmid">19523911</pub-id></element-citation></ref><ref id="bib0540"><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>H.D.</given-names></name></person-group><article-title>Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin</article-title><source>BioRxiv</source><year>2020</year></element-citation></ref><ref id="bib0545"><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N. Engl. J. Med.</source><year>2020</year></element-citation></ref><ref id="bib0550"><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>P.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection</article-title><source>Antiviral Res.</source><volume>82</volume><issue>1</issue><year>2009</year><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">19428598</pub-id></element-citation></ref><ref id="bib0555"><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name></person-group><article-title>Virus-encoded proteinases and proteolytic processing in the Nidovirales</article-title><source>J. Gen. Virol.</source><volume>81</volume><issue>4</issue><year>2000</year><fpage>853</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">10725411</pub-id></element-citation></ref><ref id="bib0560"><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Middle east respiratory syndrome</article-title><source>Lancet</source><volume>386</volume><issue>9997</issue><year>2015</year><fpage>995</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">26049252</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgement</title><p id="par0255">We acknowledge Prem Kumar Khosla, Vice Chancellor, Shoolini University, and Yeast Biology lab for support and encouragement.</p></ack></back></article>